

Review

Homocysteine, Vitamins B6 and Folic Acid in Experimental Models of Myocardial Infarction and Heart Failure—How Strong Is That Link?

Zorislava Bajic ¹, Tanja Sobot ¹, Ranko Skrbic ², Milos P. Stojiljkovic ², Nenad Ponorac ¹,
Amela Matavulj ¹ and Dragan M. Djuric ^{3,*}

- ¹ Department of Physiology, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina; zorislava.bajic@med.unibl.org (Z.B.); tanja.sobot@med.unibl.org (T.S.); nenad.ponorac@med.unibl.org (N.P.); amela.matavulj@med.unibl.org (A.M.)
- ² Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina; ranko.skrbic@med.unibl.org (R.S.); milos.stojiljkovic@med.unibl.org (M.P.S.)
- ³ Faculty of Medicine, Institute of Medical Physiology “Richard Burian”, University of Belgrade, 11000 Belgrade, Serbia
- * Correspondence: dr_djuric@yahoo.com

Abstract: Cardiovascular diseases are the leading cause of death and the main cause of disability. In the last decade, homocysteine has been found to be a risk factor or a marker for cardiovascular diseases, including myocardial infarction (MI) and heart failure (HF). There are indications that vitamin B6 plays a significant role in the process of transsulfuration in homocysteine metabolism, specifically, in a part of the reaction in which homocysteine transfers a sulfhydryl group to serine to form α -ketobutyrate and cysteine. Therefore, an elevated homocysteine concentration (hyperhomocysteinemia) could be a consequence of vitamin B6 and/or folate deficiency. Hyperhomocysteinemia in turn could damage the endothelium and the blood vessel wall and induce worsening of atherosclerotic process, having a negative impact on the mechanisms underlying MI and HF, such as oxidative stress, inflammation, and altered function of gasotransmitters. Given the importance of the vitamin B6 in homocysteine metabolism, in this paper, we review its role in reducing oxidative stress and inflammation, influencing the functions of gasotransmitters, and improving vasodilatation and coronary flow in animal models of MI and HF.

Keywords: homocysteine; vitamin B6; folic acid; myocardial infarction; heart failure; experimental models



Citation: Bajic, Z.; Sobot, T.; Skrbic, R.; Stojiljkovic, M.P.; Ponorac, N.; Matavulj, A.; Djuric, D.M. Homocysteine, Vitamins B6 and Folic Acid in Experimental Models of Myocardial Infarction and Heart Failure—How Strong Is That Link? *Biomolecules* **2022**, *12*, 536. <https://doi.org/10.3390/biom12040536>

Academic Editors: Anton Hermann and Guzel F. Sitdikova

Received: 15 February 2022

Accepted: 28 March 2022

Published: 1 April 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Cardiovascular diseases (CVD), particularly ischemic heart and brain diseases, are the leading cause of death and the main cause of disability today. The results of the Global Burden of Disease Study showed that in the period from 1990 to 2019, the prevalence of total CVD almost doubled, from 271 million to 523 million. The number of deaths from these diseases also increased, from 12.1 million to 18.6 million [1], with an estimate of reaching a staggering 23 million by 2030 [2]. Additionally, the disability-adjusted life years (DALYs) due to the ischemic heart disease reached 182 million DALYs. The burden of CVD is growing in almost all countries, and the prevalence of CVD is also rising in some highly developed countries in which a decline has previously been reported [1].

The main cardiovascular risk factors include family history of CVD, smoking, sedentary lifestyle, obesity, alcohol use, diabetes, dyslipidemia, and hypertension [3,4]. It is considered that all of these factors promote low-density lipoprotein (LDL) uptake into the vascular wall [4], causing lipid accumulation in the subendothelial layer and inducing atherogenesis. Atherogenesis is responsible for the activation of endothelial cells by monocytes and the formation of foam cells. This leads to accumulated smooth muscle cells

in artery walls that can form a fibrous atheroma cap, thereby contributing to atherosclerosis [3]. High blood pressure (hypertension) and high blood cholesterol can contribute to the exacerbation of atherosclerosis through several mechanisms, such as the renin–angiotensin–aldosterone system (RAAS), impaired endothelial function, and oxidative stress. Hypertension is also associated with a compromised regulation of methionine cycle, leading to the elevated level of homocysteine [3–5]. Elevated homocysteine concentration could damage the endothelium of blood vessels, thus participating in pathophysiology of CVD [5,6].

2. Metabolism of Homocysteine

2.1. Homocysteine Metabolism Pathway

Homocysteine (Hcy) is considered to be a marker of CVD and is known as a risk factor, in particular, for stroke, myocardial infarction (MI), heart failure (HF), cancer, Alzheimer's disease, and atherosclerosis [7–9]. Hcy is a metabolite of methionine, meaning that Hcy is also included in the folate cycle. Hcy can be formed from methionine through the process of resynthesis, or from cysteine by its degradation [10]. Hcy does not enter the body with food. Rather, it is produced from methionine in a complex process involving many steps [7,10], as follows (see also Figure 1). In a first step, the adenosine group is converted from ATP to methionine with the help of the enzyme S-adenosyl methionine (SAM or AdoMet), which is a synthetase also referred to as methionine adenosyltransferase (MAT). In a subsequent step, SAM delivers the methyl group to recipient molecules, such as proteins, RNA, DNA, and neurotransmitters. This process is known as one-carbon metabolism. More than 100 different methyltransferases are involved in this process, resulting in the formation of the S-adenosyl Hcy (AdoHcy), which acts as an inhibitor of most methyltransferases [7,10].

In the next step, L-homocysteine is formed by means of AdoHcy hydrolase (SAHH). The reaction here goes in both directions, although it is predominantly in the direction of AdoHcy synthesis [7,10]. Additionally, adenosine can result from this reaction, but can also result from AMP via 5'-nucleotidase. In adenosine metabolism, adenosine forms inosine by adenosine deaminase (ADA). From here, inosine produces hypoxanthine by means of nucleosidase. Thereafter, hypoxanthine forms xanthine and uric acid via xanthine oxidase [3]. Hcy and adenosine should be expelled from the cell to prevent their accumulation [7,10]. Adenosine can modulate inflammation and immune response. Accumulation of adenosine is associated with CVD, especially in myocardial ischemia [3]. It is also worth noting that excessive accumulation of AdoHcy is harmful, since it can lead to general DNA hypomethylation [7].

Newly formed L-homocysteine can now undergo two processes: (i) remethylation, where L-methionine is formed as the product, and (ii) transsulfuration, where L-cysteine is formed as the product. *Remethylation* is a process in which Hcy is transformed to methionine. This reaction involves methionine synthase (MS), an enzyme that links homocysteine to folate metabolism [11]. The cofactor cobalamin (Cbl or vitamin B12) is necessary for the action of this enzyme. Together, they form the Cbl (I) MS complex, which in its turn binds the methyl group of 5-methyl tetrahydrofolate (5-MTHF). 5-MTHF then serves as a donor of methyl group. Oxidation of cobalamin forms an inactive Cbl (II) MS complex. Methionine synthase reductase (MSR) reactivates the Cbl (II) MS complex by reduced methylation, where AdoMet serves as a methyl donor [10]. The result of this remethylation pathway is the formation of methionine and tetrahydrofolate (THF). As enzyme MS is present in all parts of the human organism, this type of remethylation can take place anywhere in the body. Furthermore, the remethylation process can occur in the liver and kidneys with the enzyme called betaine-homocysteine methyltransferase (BHMT). In this case, betaine (trimethyl glycine) acts as a methyl group donor. A cofactor of this enzyme is zinc, and the products of these reactions are dimethylglycine (DMG) and methionine [7].




Figure 1. Homocysteine metabolism and folate cycle. ADA—adenosine deaminase, ADMA— asymmetric dimethylarginine, AdoMet—S-adenosyl methionine, AdoHcy—S-adenosyl homocysteine, B2—vitamin B2, B6—vitamin B6, B9—vitamin B9, B12—vitamin B12, BH2—dihydropterin, BH4—tetrahydrobiopterin, BHMT—betaine homocysteine methyltransferase, CBS—cystathionine β-synthase, CSE—cystathionine γ-lyase, DHF—dihydrofolate, DHFR—dihydrofolate reductase, DMG— dimethylglycine, dTMP—deoxythymidine monophosphate, dUMP—deoxyuridine monophosphate, eNOS—endothelial NOS, GS—glutathione synthase, GSH—reduced glutathione, H₂S—hydrogen sulfide, MAT—methionine adenosyltransferase, MetRS—methionyl-tRNA synthetase, MS—methionine synthase, MSR—methionine synthase reductase, MTHFD—methylene tetrahydrofolate dehydrogenase, MTHFR—methylene tetrahydrofolate reductase, NO—nitric oxide, NOS—nitric oxide synthase, NS—nucleosidase, PON 1—paraoxonase 1, ROS—reactive oxygen species, SAHH—S-adenosyl homocysteine hydrolase, SAM—S-adenosyl methionine, SHMT—serine hydroxymethyltransferase, THF—tetrahydrofolate, TYMS—thymidylate synthase, XO—Xanthine oxidase, 5’NT—nucleotidase. The ability of H₂S to increase NO bioavailability by activating eNOS is depicted with the dashed arrow. Arrows pointing up (↑) next to substance or enzyme represent increased level of substance or increased enzyme activity, and arrows pointing down (↓) represent decreased level of substance or decreased enzyme activity.

Transsulfuration is the process during which homocysteine forms cysteine. This process includes two enzymes, cystathionine β-synthase (CBS) and serine. The catalyst of the reaction is cystathionine γ-lyase (CSE), which hydrolyses cystathionine to cysteine and α-ketobutyrate. These are the two key enzymes in the production of hydrogen sulfide (H₂S)

from cysteine. H₂S can also be a result of the reaction of homocysteine and cysteine, catalyzed by CBS [12]. Vitamin B6 (pyridoxal-5'-phosphate) is required for the action of both enzymes, CBS and CSE [7,10,13–15]. Cysteine produced in the process of transsulfuration can be used for synthesis of glutathione (GSH) and proteins [16]. As already mentioned, B vitamins (B6, B12, B2) are necessary for the normal metabolism of Hcy. Deficiency of these vitamins can cause accumulation of Hcy and can lead to toxic effects including cell and tissue damage [7].

The abovementioned toxic effects of Hcy are a result of the following: inhibition of Na⁺, K⁺ ATPase, oxidative stress, inhibition of acetylcholinesterase, inhibition of production of gasotransmitters (NO, CO, H₂S), overstimulation of N-methyl-D-aspartate (NMDA) receptors, and inhibition of cardiac tissue respiration [13]. Hcy can appear in several forms, including as mixed homocysteine disulfides and s-homocysteinylated proteins. The reduced form of homocysteine accounts for less than 1% of total Hcy. Oxidized forms (S-homocysteinylated proteins and N-homocysteinylated proteins) account for approximately 80% of total Hcy. The precursor of N-homocysteinylated proteins is homocysteine thiolactone (HTL) [17]. In physiological conditions, the concentration of HTL is low. However, hyperhomocysteinemia (HHcy) is characterized by a larger amount of HTL. The reaction leading to HHcy is catalyzed by methionyl-tRNA synthetase (MetRS), as depicted in Figure 1 [13,18]. In vitro studies in human cells and serum have shown that HTL undergoes two reactions: (i) homocysteinylated protein on a lysine residue, and (ii) enzymatic hydrolysis to Hcy by a calcium-dependent hydrolytic enzyme called paraoxonase 1 (PON1) [18,19].

PON1 is produced in the liver, and in the circulation it binds high-density lipoprotein (HDL) [20], contributing to anti-inflammatory, antioxidative, and antiatherothrombotic effects of HDL [18,19]. Animal and human studies have shown that PON1 has a protective effect against atherosclerosis induced by a high-fat diet [21,22].

2.2. Folate Metabolism

Folate metabolism is closely related to Hcy metabolism (Figure 1) [7,10,23]. It acts as a methyl donor in the homocysteine remethylation process [10]. Folate is one of the B complex vitamins, and it is essential for the functioning of specific enzymes. The primary metabolite of folate is 5-MTHF [24]. 5-MTHF enters the blood circulation from intestinal cells and is transported via blood to specific cells. The conversion of folate to 5-MTHF is limited. This enables organism to deal with ingestion of substantial amounts of folates by not converting them all, but instead circulating them in non-metabolized form. In this case, it enters the cell, and dihydrofolate (DHF) is reduced to THF by dihydrofolate reductase (DHFR) [24]. The enzyme serine hydroxymethyltransferase (SHMT) can directly convert THF to 5,10-methylene THF. SHMT uses serin as a carbon donor, and requires vitamin B6 for its normal function [10].

In the cycle of folate, when 5,10-methylene THF acts as a co-substrate for the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), 10-formyl THF gives a carbon group for purines biosynthesis (Figure 1). Enzyme thymidylate synthase (TYMS) participates in conversion of dUMP to dTMP. This process produces dihydrofolate (DHF). Dihydrofolate reductase reduces DHF to THF. In addition to being a cofactor in the formation of dTMP, 5,10-methylene THF is reduced to 5-MTHF by the methylenetetrahydrofolate reductase (MTHFR). The normal function of MTHFR is dependent on riboflavin (vitamin B2). However, TYMS and MTHFR compete for 5,10-methylene THF. That makes MTHFR the major enzyme for controlling 5-methyl THF production in the process of homocysteine remethylation [7,10]. 5-methyl THF is an active form of folate circulating in plasma. It is transported to the target cells of peripheral tissues and is used in cellular metabolism [25]. Folate deficiency leads to hyperhomocysteinemia [7,10].

2.3. The Role of Vitamins B6 and B12 in Homocysteine Metabolism and the Folate Cycle

Vitamins B6 and B12 have very important functions in one-carbon metabolism, and through that they are linked to the metabolism of Hcy [26,27]. Vitamin B6 is important in the process of transsulfuration of Hcy metabolism. Namely, vitamin B6 participates in the reaction in which Hcy transfers a sulfhydryl group to serine to form α -ketobutyrate and cysteine (Figure 1). Cysteine is a precursor of the main antioxidant component, glutathione (GSH). In the process of transsulfuration, vitamin B6 is a cofactor necessary for the normal function of the enzymes CBS and CSE. An insufficient amount of methionine induces a homocysteine remethylation reaction, resulting in methionine synthesis. This reaction requires 5-methyltetrahydrofolate as a substrate and vitamin B12 as a cofactor for MS [28]. Another important role of vitamin B12 is its role as a cofactor for SHMT, which converts THF to 5,10-methylene THF [10].

2.4. Metabolic Disorders Related to Altered Homocysteine Metabolism

Hyperhomocysteinemia (HHcy), increased concentration of Hcy in plasma, can be classified as mild (15–30 $\mu\text{mol/L}$), medium (30–100 $\mu\text{mol/L}$) or severe (more than 100 $\mu\text{mol/L}$). The causes of HHcy fall into the following five categories: (i) enzyme disorder, (ii) cofactor deficiency, (iii) excessive methionine intake, (iv) specific diseases such as chronic renal failure, hypothyroidism, anemia, or malignant tumors, and (v) intake of specific drugs such as cholestyramine, methotrexate, oral contraceptive pills, phenytoin, carbamazepine, or metformin [7,29]. These five categories of HHcy causes are discussed in detail in the following paragraphs.

As indicated above, one of the common causes of HHcy in Hcy metabolism is enzyme disorders, i.e., deficiency or genetic effects. For example, deficiency of the enzyme CBS may lead to elevated Hcy concentrations due to its pivotal role in the conversion of Hcy to cystathionine. When this enzyme does not perform its function in the transsulfuration process, an insufficient amount of Hcy converts into cystathionine. Additionally, genetic defects of the enzymes MTHFR and MS pose a risk of HHcy [7].

HHcy can be also caused by the deficiency of cofactors involved in the metabolism of Hcy, namely vitamins B2, B6 and B12 [30]. These vitamins are water soluble and therefore easily excreted in the urine. Deficiency of vitamins B12 and B2, which participate in the remethylation process, and deficiency of vitamin B6, as a cofactor in the process of transsulfuration, often occurs in the elderly population. As a consequence, HHcy is more common in the ageing population [31]. There is a 2.5-fold increase in HHcy with folate deficiency, and a 2.6-fold increase with vitamin B12 deficiency [32].

Methionine, as an essential amino acid, is the only source of Hcy in food. A methionine-rich diet stimulates Hcy production. Mice fed with the methionine or Hcy-rich diets had higher concentrations of homocysteine-thiolactone in the urine compared to mice fed with a balanced diet. Plasma homocysteine-thiolactone concentrations were also elevated, although this difference was not significant [33].

Renal failure, hypothyroidism, anemia, and malignant tumors are all associated with HHcy. In renal failure, HHcy can be caused by reduced glomerular filtration and renal excretion [34]. In addition, the kidney tissue can contain the enzymes involved in the process of remethylation and transsulfuration. However, in chronic renal failure, these enzymes are inactive. HHcy in renal failure can also occur due to non-renal causes such as impaired folate metabolism [35].

Elevated Hcy concentrations are present in patients with clinical and subclinical forms of hypothyroidism [36,37]. There are no consistent data on the HHcy mechanism for this condition. There is a correlation between elevated concentrations of Hcy and Hashimoto thyroiditis (the most common cause of hypothyroidism). Patients with iatrogenic hypothyroidism have higher Hcy concentrations compared to those without hypothyroidism. This suggests that immunological inflammatory diseases can increase Hcy levels [38]. Vitamin B12 and folate deficiency can cause megaloblastic anemia. These vitamins are necessary for normal Hcy metabolism, and their deficiency can lead to HHcy [7].

Furthermore, Vitamin B12 and folate deficiency can also be found in various neoplasms. Tumors impair normal Hcy metabolism mostly due to folate deficiency [39,40]. Tumor cells release substantial amounts of Hcy. Rapidly proliferating tumor cells use folate for their metabolism and inactivate the remethylation process catalyzed by MS, causing HHcy [41].

HHcy is associated with DNA damage and neurotoxicity by increased N-methyl-D-aspartate (NMDA) receptor expression [42,43]. HHcy also alters the bone microarchitecture and increases the risk of bone fracture [44]. An experimental study showed that Hcy can reduce the activity of cardiac acetylcholinesterase and alter heart function [45].

2.5. Consequences of Homocysteine, Folate, and Vitamin B6 Metabolism-Related Disorders

The mechanism by which Hcy causes or participates in the onset of certain diseases has not yet been fully understood on the basis of the current literature. Elevated Hcy levels have been found in different pathological conditions, such as CVD, diabetes, vision and hearing impairment, cognitive dysfunction, hypertension, carcinomas, and bone fractures.

The relationship between Hcy and CVD requires special attention. Namely, it is considered that HHcy can cause damage to endothelial function [7,13]. Endothelial dysfunction is the basis for the development of CVDs [46]. Therefore, in this section, the focus will be on the Hcy, folic acid, and vitamin B6 metabolism disorders in relation to CVDs.

2.5.1. Homocysteine and CVD

Elevated Hcy concentration affects blood vessels and could be responsible for the worsening of atherosclerosis by means of damaging the blood vessel wall [6]. Endothelial cells are sensitive even to moderate concentrations of Hcy. Elevated Hcy concentration can alter vascular endothelial functions—its surface changes its characteristics from an anticoagulant to a procoagulant state [47]. Hcy stimulates the production of the platelet thromboxane A2 [48]. HHcy activates coagulation factor V, resulting in the impairment of protein C activation and thrombomodulin expression. Elevated Hcy concentration reduces the efficacy of anticoagulant substances and inhibits their DNA synthesis [49]. Hcy and its thiolactone form inhibit the activity of lysyl oxidase (an enzyme that participates in the maturation of the extracellular matrix) in the cells of the vascular endothelium [50]. Hcy and Hcy compounds also induce depression of heart contractility and coronary flow [51,52] and decrease oxygen consumption [53]. In vitro study has shown that incubation of isolated rat femoral artery with Hcy damages the vascular endothelium via discrete or expressed interruption of endothelial cells [54]. The key pathophysiological mechanism of Hcy-induced atherosclerosis is its ability to stimulate production of reactive oxygen species (ROS). Auto-oxidized sulfhydryl groups of Hcy stimulate the production of ROS leading, in turn, to deactivation of endothelial nitrogen monoxide (NO). High concentrations of Hcy disturb the activity of glutamate-cysteine ligase (previously known as gamma-glutamylcysteine synthetase). This enzyme is responsible for de novo glutathione synthesis [55]. Consequently, the concentration of glutathione decreases, leading to a reduction in the detoxification of ROS. As glutathione reduces ROS production and stimulates NO production, reduced concentration of glutathione can, therefore, directly and indirectly cause the hypercoagulable state on the endothelial surface [56]. HHcy stimulates the proliferation of smooth muscle cells in the blood vessels intima (and they increase collagen synthesis). This leads to an irregular extracellular matrix formation, which affects the appearance and worsening of atherosclerosis [57,58]. Smooth muscle cells increase collagen synthesis in the presence of Hcy. High Hcy concentrations cause a condition similar to inflammation due to an interaction between endothelial cells and neutrophils, as well as neutrophil migration [57]. Experimental studies have shown that a high-methionine diet induces HHcy, leading to impaired myocyte contractility, increased cardiac remodeling, and procoagulant properties in the endothelium [59–63]. These studies also showed that statins attenuate Hcy-induced myocyte contractility impairment [62,63]. Elevated levels of Hcy also lead to hyperuricemia. Uric acid increases the amount of ROS, which causes a decrease in the bioavailability of NO and results in endothelial dysfunction [64].

Endothelial dysfunction plays an important role in all stages of coronary artery disease (CAD) [65]. All of the abovementioned mechanisms involved in endothelial dysfunction also participate in the development of atherosclerotic CAD [66]. The role of folic acid and vitamins B6 and B12 in the metabolism of Hcy is already known [7], and the literature confirms that the consumption of B-group vitamins reduces Hcy level in the circulation [67]. These vitamins help in the treatment and/or prevention of Hcy metabolism disorders. The results of a study investigating the primary prevention of CAD by folic acid supplementation showed an inverse relationship between high doses of folic acid (200 $\mu\text{mol}/\text{day}$) and the incidence of CAD in follow-up period of 10.7 years [68]. The primary prevention and protective effects of folic acid and vitamins B6 and B12 were the focus of a large Japanese study in which a significant inverse relationship of the highest and the lowest folate levels with CAD mortality in women was found [69]. Several studies have shown that folic acid and vitamin B12 supplementation can lower Hcy concentration [70], and supplementation with folic acid can improve damaged vascular endothelial function in CAD [71]. HHcy is also positively correlated with the severity of CAD [72]. Another study showed a positive correlation between Hcy level and CAD, as well as significant negative correlation between Hcy levels and folic acid concentration in all CAD categories [66]. Another study [73] found that AMI patients had lower levels of pyridoxal phosphate (PLP) and folic acid compared to healthy individuals. Hcy levels were higher than in the control group, although there were also no significant differences [73].

Stroke is another clinical condition associated with atherosclerosis, HHcy, and reduced concentrations of folic acid and B vitamin. The meta-analysis of 19 randomized controlled trials included an analysis of the effects of folic acid and vitamins B6 and B12 on Hcy concentration, primary prevention of CVDs, and mortality. The results showed that the incidence of stroke was significantly reduced by the use of folic acid and B6 and B12 vitamins [74]. A large randomized double-blind study, the China Stroke Primary Prevention Trial (CSPPT), focused on the primary prevention of stroke in subjects with hypertension. The results showed that the risk of the first ischemic stroke and other cardiovascular events, such as MI and cardiovascular death, was lower in the group co-treated with antihypertensive therapy and folic acid [75]. A meta-analysis of three large randomized control studies—Vitamin Intervention for Stroke Prevention (VISP), Vitamins to Prevent Stroke (VITATOPS), and Heart Outcomes Prevention Evaluation 2 (HOPE-2)—focused on the protective effects of folic acid plus B vitamins [76]. The results showed a lower incidence of recurrent stroke in a group of patients receiving folic acid and vitamins B6 and B12 [77–80]. Another meta-analysis showed that treatment with folic acid alone or in combination with vitamin B12 was associated with a lower risk of recurrent stroke [81].

HHcy due to reduced concentration of vitamins B6, B12 and folic acid is considered a part of the venous thrombosis pathophysiological mechanism [82]. A mutation in the MTHFR gene, as well as HHcy, increases the risk of deep vein thrombosis (DVT) [83]. The results of a clinical study [84] showed that 15% of patients with DVT had HHcy, of which 43.3% had decreased folic acid concentration (less than 3 ng/mL), 1.6% had decreased vitamin B12 concentration (less than 150 pmol/L), and 3.33% had decreased vitamin B6 concentration (less than 30 nmol/L). The average Hcy concentration was higher in women compared to men, and a significant correlation was found between Hcy concentration and age [84]. Namely, patients with DVT older than 40 years had higher Hcy concentrations than the younger age group. This difference could be explained by the prevalence of CVD, cognitive disorders, and depression in the elderly (conditions associated with HHcy) [15]. An increase in Hcy concentration by 5 $\mu\text{mol}/\text{L}$ increases the risk of all-cause mortality by 27%, the risk of CVD by 32%, and CAD by 52% [85]. This risk increases with age [85]. The available literature also shows that HHcy in women older than 40 years is a risk factor for DVT [84].

Considering that a plethora of CVDs, including CAD, MI, heart valve disease, and hypertension, can lead to heart failure (HF) [86], it is important to analyze the relationship between Hcy and HF. In vitro research on cardiovascular cells and tissue showed the

sensitivity of myocardial cells to damage caused by Hcy [87]. Clinical study with chronic HF patients found a correlation between HHcy and increased mortality rate [88]. The mechanism by which Hcy affects HF is unknown, and it is unclear whether HHcy may be a direct cause of HF. Heart diseases in general and HF in particular, are complex, and are influenced by so many factors that it cannot be concluded that Hcy is the only factor that can cause or worsen HF [7]. It can be considered as a possible marker of dyslipidemia, and can therefore be used as a factor influencing the deterioration and progression of CVD [89]. There are also indications that Hcy can be used as a prognostic marker of long-term heart complications in patient with chronic HF [90].

2.5.2. Homocysteine and Diabetes

Diabetes mellitus (DM) can alter Hcy metabolism [91]. Hypomethylated genomic DNA has been found in diabetic rats [92]. Folate is involved in SAM synthesis, which acts as a methyl donor for the proteins DNA and RNA [7]. Clinical studies have shown the beneficial effects of folic acid supplementation in patients with DM, and these include reduced Hcy concentration, reduced fasting insulin, and better control of glycemia [93,94]. Animal studies have also shown the beneficial effects of folic acid in streptozotocin-induced diabetes mellitus in rats. The results of these studies showed hepato- and cardio-protective effects as well as glycemia reduction in diabetic rats treated with folic acid [95,96]. Folic acid also reduces cardiomyocyte apoptosis in experimentally induced diabetic rats [97].

Vitamin B6 has an inverse relationship with DM. Deficiency of vitamin B6 is associated with DM complications. Pyridoxal 5'-phosphate (PLP) concentration is inversely related to complication in DM patients [98]. A study on alloxan-induced diabetic rats showed a significant reduction in blood glucose level, better physical performance, and decreased ROS production and damage of DNA after administration of vitamin B6 [99]. Since oxidative stress plays a significant role in DM, it is considered that a low level of vitamin B6 cannot fulfil its antioxidant function [100].

2.5.3. Homocysteine and Drugs

Lipid-lowering drugs, diabetes drugs, sex hormones, antirheumatic drugs, antiepileptic drugs (and other such as levodopa, acetylcystein, cyclosporin) can alter Hcy metabolism. Namely, lipid-lowering drugs can increase levels of Hcy, but the mechanism by which fibric acid derivatives do that is not well understood. Nicotinic acid can increase Hcy level via inhibition of pyridoxal kinase, decreased vitamin B6 level, and increased CBS activity. Cholestyramine increases Hcy level by interfering with folate and vitamin B12 absorption. Insulin increases MTHFR activity and decreases CBS activity, causing the Hcy level to decrease. Sex hormones can increase or decrease Hcy concentration, estrogens causing a decrease and androgens causing an increase. Methotrexate inhibits activity of DHFR and causes increased Hcy levels. Phenytoin and carbamazepine increase Hcy via folate depletion and possible hepatic enzyme induction, and phenytoin alone also via a possible decrease in 5-MTHFR and methionine synthase activity. Levodopa is a substrate for AdoMet-dependent transmethylation, and it increases Hcy concentration. Acetylcysteine decreases Hcy via thiol-sulfide exchange. Cyclosporine can increase Hcy concentration through possible interference in the remethylation process of Hcy metabolism [29].

3. Oxidative Stress in Animal Models of MI and HF—The Importance of Homocysteine, Vitamin B6, and Folic Acid

Oxidative stress affects the development and progression of clinical and experimental HF. Oxidative stress is defined as an imbalance between the production of reactive oxygen species (ROS) and the endogenous antioxidant defense mechanism. When present in low concentrations, ROS play a significant role in cell homeostasis. Excess of ROS, on the other hand, can cause cell dysfunction and, in some cases, even cell death. Accumulation of ROS in the heart can cause the development and progression in myocardial remodeling, leading to HF [101]. ROS participates in changes of proteins that are responsible for myocardial

contractions (calcium “L”-type channels, sodium channels, potassium channels, and sodium potassium channels). In this way, ROS affect the contractility of heart muscle. ROS alter activity of the sarco(endo)plasmic reticulum Ca^{2+} -ATPase (SERCA) and reduce the sensitivity of myofilaments to calcium. Furthermore, ROS induce fibroblast proliferation and activation of heart matrix metalloproteinases, leading to extracellular remodeling [102]. In mice, induced MI increases ROS production, leads to dilatation of the left ventricle, contractile dysfunction, and remodeling. In addition to a drastic increase in oxidative stress, HF is characterized by depletion of the innate antioxidant defense mechanism. In cardiomyocytes, as well as in most cells, the main endogenous components of the antioxidant defense mechanism are superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), nicotinamide adenine dinucleotide (NAD^+) and glutathione (GSH). Several studies have noted significant reductions in SOD, catalase, and GPx activity in animal models of HF [103–105]. Mice with myocardial injury had reduced activity of SOD and GPx and worse outcomes in comparison to their controls [106–110]. NAD^+ together with reduced NADH is crucial in initiating the oxidation-reduction reactions responsible for energy production [101]. In addition to its role in the regulation of cellular energy metabolism, NAD^+ is a precursor for the phosphorylated nucleotide pair $\text{NADP}^+/\text{NADPH}$ which plays a leading role in detoxifying ROS. Decreased levels of myocardial NAD^+ have been found in several animal models of HF. The literature shows significantly reduced activity of nicotinamide mononucleotide adenylyl transferase (Nmnat) in animal models of HF and in patients. This enzyme is responsible for NAD^+ production [111]. This observation indicates that a decrease in NAD^+ also occurs in humans. GSH, like NAD^+ , is one of the main antioxidants in mammalian cells. It scavenges radicals and eliminates the products of lipid peroxidation. In an animal model of MI, total GSH was decreased [112,113].

Vitamin B6 is a coenzyme in the glutathione-based antioxidant defense system. Pyridoxal phosphate (PLP) can act as a coenzyme of transsulfuration, allowing the conversion of Hcy to cysteine. Cysteine is involved in the synthesis of reduced glutathione (GSH). In addition to GSH, GPx, glutathione reductase (GR), and glutathione S-transferase (GST) also participate in cellular antioxidant defense [114]. Vitamin B6 deficiency can induce impairment of antioxidative defense mechanism, and thus contribute to oxidative stress. Experimental studies have shown that the antioxidant effect of vitamin B6 is based on the inhibition of xanthine oxidase. Xanthine oxidase and xanthine dehydrogenases represent two faces of oxidoreductase, an enzyme with a significant role in the final stage of purine catabolism and the formation of uric acid and hydrogen peroxide [115]. In animal models of MI, PLP reduced the size of the infarcted lesion and improved cardiac function [116]. As mentioned earlier, vitamin B6 deficiency is associated with HHcy, which is considered to be a risk factor for atherosclerosis. Studies in animal models showed higher level of lipid peroxide in a group of rats deficient in vitamin B6, as well as in a group treated with Hcy, compared to the control group [117]. During oxidative stress, methionine synthase activity is reduced, causing reduced methionine synthesis, while transsulfuration reactions are shifted toward GSH synthesis [118].

Preclinical studies showed that vitamin B6 supplementation could lead to a decrease in Hcy concentration and reduction of oxidative stress, and have a beneficial effect on markers of cardiac function [119].

Folic acid is a free radical scavenger that acts as an antioxidant, protecting the organism from damage caused by accumulation of free radicals. It can act directly or indirectly by competitive inhibition of xanthine oxidase [120]. Its antioxidant role is very important in CVDs [121]. Experimental research has shown that a fat-rich diet in rats causes impairment of cardiac function, but supplementation with folic acid improves left ventricle function [122]. As already mentioned, the folic acid metabolism is related to Hcy metabolism. Intake of a large amount of folic acid increases Hcy remethylation, resulting in a decrease in Hcy level. Folic acid supplementation could therefore decrease Hcy level and cardiovascular risk. Folic acid supplementation can affect posttranslational protein modulation, which can favorably affect the heart contractile function [122]. Studies have

shown that folic acid mitigates the oxidative stress induced by HHcy [123]. ROS also damages cell DNA, but folic acid regulates cell growth and DNA repair, especially in HHcy, thus participating in antioxidant protection [124].

Models of HF induced by a single dose of monocrotaline showed that co-application of folic acid and vitamin B6 decreased SOD, GPx activity, and glutathione levels [125,126]. The importance of folate pretreatment in a model of cardiotoxicity caused by doxorubicin showed reduced production of superoxide anions, resulting in a reduction in oxidative stress [127]. Folic acid also increases the coronary flow and nitrite outflow in isolated rat hearts [128] and improves endothelial function in CAD in humans [129,130].

4. Inflammation in Animal Models of Myocardial Infarction and Heart Failure—Significance of Homocysteine, Vitamin B6 and Folic Acid

Endothelial dysfunction has a key role in the inflammatory process of atherosclerosis. Vascular inflammation is a consequence of the inability of endothelial cells to counteract ROS, causing increased production of cytokines and smooth muscle cell proliferation. These changes can impair heart function [131].

The regional response after ischemic MI can be divided into four phases [132,133]: (i) necrosis phase, (ii) acute inflammatory phase, (iii) subacute granulation phase, and (iv) chronic scar phase. The necrosis phase occurs immediately after MI cells die and is characterized by necrosis and apoptosis. The acute inflammatory phase corresponds to an inflammatory response that occurs in the first seven days after ischemic MI onset (and the aim of this phase is to absorb necrotic tissue). The subacute granulation phase corresponds to the formation of granulation tissue consisting of proliferated myofibroblasts, which increases the tension strength of the heart muscle, and the proliferation of blood vessels to improve perfusion and enable better cell survival. This phase typically lasts one to three weeks. The chronic scar phase occurs after a month, and is characterized by the formation of fibroblasts, the regression of small blood vessels, and the formation of final scar tissue rich in collagen [134].

The systemic inflammatory response consists of: humoral (cytokines and complement system) and cell-mediated response [134]. The healing process after MI is initiated by TNF- α , IL-6 and IL-1 [135–137]. Ischemia and other factors, such as damaged myocytes and ROS, stimulate TNF- α in the acute postinfarction phase. In the early postinfarction phase, a certain level of cytokine production is physiological because it reduces cellular apoptosis. The complementary system stimulates cytokine production (e.g., interleukin-8). These cytokines, together with activated platelet factor (produced in endothelial cells), stimulate the endovascular adhesion of neutrophils [136,137]. These processes increase vascular and tissue inflammation. Excessive regional inflammatory response can have a detrimental effect on the infarct zone, even leading to an increase in the affected zone. Neutrophils, monocytes/macrophages, and mast cells participate in the inflammatory cell-mediated response. Neutrophils from blood vessels migrate to the infarcted zone, where they can reduce local perfusion and lead to an increase of thromboxane B2. As a result, vasoconstriction and platelet aggregation can occur in this area. Monocytes, which become macrophages and secrete various cytokines and growth factors, can also migrate into the damaged heart tissue [134]. Degradation of mast cells leads to the release of fibroblast growth factors, endothelial growth factors, histamine, and other factors that promote fibrosis and angiogenesis in the myocardium, thus participating in the formation of the final scar tissue [138,139].

C reactive protein (CRP) levels increase after acute MI due to cytokine activation, and it binds to damaged heart muscle cells. This stimulates the cascade of complement components, which can lead to an increase in the size of the infarct zone. In addition, it has proatherogenic and prothrombotic characteristics, so it can be used as a marker of acute MI [134]. The production of IL-6 is stimulated by interferon gamma, IL-1, and TNF- α [140,141]. It affects the inflammatory response and platelet aggregation, and stimulates the proliferation of vascular smooth muscle cells (acts as a procoagulant) [142]. IL-1

is also involved in inflammation after MI. IL-1 receptor type I (IL-1RI) is associated with post-MI inflammation, impaired ventricular function, and scar formation [143–145]. IL-18 pretreatment in ischemia/reperfusion models showed significant decreases in infarct size [146].

Vitamin B6 (in the form of PLP) affects the acute inflammation phase after acute MI. It is necessary for the production of cytokines, which are involved in the chronic phase of inflammation, and in the proliferation and activation of lymphocytes [147]. Studies have shown a transient decrease of PLP after acute MI [148,149]. It is known that increasing vitamin B6 levels decrease inflammation, but it has been suggested that a deficiency of vitamin B6 also increases the risk of inflammation or inflammatory diseases [150–152]. It has been shown that vitamin B6 lowers CRP [147].

The anti-inflammatory effect of folic acid consists of the reduction of some inflammatory mediators, and it is considered to be a potential drug that has protective effect in CVDs [153]. Decreased folate concentrations can increase inflammation [154]. Another confirmation of the anti-inflammatory effect of folate is that a folate-rich diet reduces the level of IL-6 [155]. Animal models of early atherosclerosis (apoE mice) showed the positive effect of high doses of folic acid on inflammatory status and cholesterol level [156].

In addition to acting as a procoagulant, Hcy in high doses contributes to vascular inflammation. Experiments on ApoE mice showed a 19-fold higher Hcy concentration in the group of mice fed a methionine-rich food (methionine is a substrate for Hcy synthesis) compared to the control group. HHcy was induced in mice with methionine-rich diet, but low folate and vitamins B6 and B12 was associated with increased atherosclerotic lesions in the aortic sinus compared to the control group. The characteristics of these atherosclerotic lesions are an increased number of macrophages and smooth muscle cells. In the same group of mice, expression of vascular cell adhesion molecule/protein 1 (VCAM-1) was 3.7-fold higher [157]. Expression of these molecules is at least partly mediated by activation of NF- κ B [158,159], a transcription factor associated with the proinflammatory response [160,161].

5. Gasotransmitters in Animal Models of Myocardial Infarction and Heart Failure—Significance of Homocysteine, Vitamin B6 and Folic Acid

Gasotransmitters are a group of regulatory molecules that participate in physiological and pathological functions in mammalian tissues. Nitric oxide (NO), hydrogen sulfide (H₂S), and carbon monoxide (CO) are involved in many physiological functions [12]. In cardiovascular systems, H₂S and NO participate in vasorelaxation, stimulation of angiogenesis, and cardioprotection [162,163]. CO participates in relaxation of smooth muscle cells of coronary blood vessels and in cardioprotection [164]. These gasotransmitters have antioxidative potential, by means of which they can fulfill their cardioprotective role [165].

5.1. Nitric Oxide

In mammalian tissue, NO is a result of enzymatic and non-enzymatic reactions. The enzyme NO synthase (NOS) produces NO by converting L-arginine to L-citrulline [166]. There are three isoforms of NOS: neural (nNOS), endothelial (eNOS), and inducible (iNOS). The presence of eNOS in the vascular endothelium is particularly important for cardiovascular physiology [12]. Its task is to maintain basal vascular tone by secreting a small amount of NO. NO has been the subject of many studies in ischemic/reperfusion myocardial injury, and eNOS deficiency exacerbates this type of myocardial injury [167]. Along with eNOS, L-arginine reacts with oxygen radicals, which are reduced by NADPH to form NO radicals and L-citrulline. The availability of L-arginine is particularly important for maintaining adequate NO production. The uptake of L-arginine into endothelial cells is enabled by the systemic transporter of γ + cationic amino acids (Cat). Prolonged incubation with a significant concentration of Hcy in bovine aortic endothelial cells leads to a significant dose-dependent decrease in Cat-1 isoform expression [168]. This leads to decreased transmembrane transport of L-arginine, reduced NO production, and suppressed

vasodilation after acetylcholine administration [169]. It is not known why Hcy changes L-arginine transport via Cat-1, but it is suggested that oxidative stress induced by Hcy plays an important role, because the function of γ^+ can be improved with antioxidants [168]. When the amount of L-arginine is small, NO synthesis decreases, and a phenomenon called eNOS “uncoupling” occurs. eNOS is heterodimer comprising of two reductase domains linked to another pair of oxygenase domains. In the reductase domains, electrons from NADPH reduce oxygen with heme as a cofactor. Then the iron-dioxygen complex oxidizes L-arginine to form NO in the oxygenase domain. In the absence of L-arginine, the oxygenase domain, necessary for NO production, is impaired. The reductase domain continues to reduce oxygen, leading to superoxide production. eNOS is thus “uncoupled” [170]. In vitro experiments on Hcy-treated human umbilical vein endothelial cell cultures showed the presence of uncoupled eNOS. The results of this study showed that ROS production was proportional to the activity of eNOS. The results also showed a reduction in the availability of tetrahydrobiopterin (BH4) by 80% [169].

Superoxide from uncoupled eNOS and increased NADPH oxidase reduces residual NO from the still-functional eNOS. The product of this reaction is peroxynitrite. Peroxynitrite is an oxidizing agent that oxidizes and decreases the level of BH4. Progressive reduction of BH4 due to peroxynitrite production may trigger a cycle in which eNOS uncoupling is further impaired. This increases BH4 destruction [171]. Another mechanism by which Hcy impairs the endothelial function and dilation is through the asymmetric dimethylarginine (ADMA) molecule pathway. L-arginine incorporated into proteins goes through methylation, then, with the help of the enzyme protein-arginine methyltransferase, ADMA is synthesized during the posttranslational protein change [172]. Methylated protein hydrolyzed during protein turnover releases ADMA. Due to its structural similarity to L-arginine, ADMA competes with L-arginine to inhibit eNOS [173]. The main pathway of ADMA metabolism is the production of citrulline methylamine, a reaction catalyzed by dimethylarginine dimethylaminohydrolase (DDAH). A small fraction of ADMA is metabolized to α -keto acids or excreted by kidneys.

Hcy can influence DDAH activity, thus preventing ADMA metabolism, resulting in a reduced amount of NO [174]. During ischemia, pH in tissue decreases, and the oxygen-dependent activity of NOS becomes limited, which makes the production of NO by NOS-independent enzymatic and non-enzymatic reduction of endogenously created nitrites or nitrates particularly significant [12]. In myocardial ischemia, NO is a potent vasodilator that allows perfusion of damaged myocardium [175]. NO reversibly inhibits respiration in mitochondria, which allows better cellular oxygenation in tissues distant from blood vessels [176,177]. NO is also important because it inhibits the adhesion of neutrophil to the endothelium of blood vessels. This is important, because neutrophilic adhesion stimulates the activation of other leukocytes and the production of superoxide radicals, which further damage the endothelium and myocardium [178,179]. NO also has an antiaggregating role [180], and it inhibits apoptosis [181].

Nitrites and NO alleviate myocardial damage. For this reason, donors of nitrites and NO could be potential agents for the reduction of infarcted lesions. In this context, sodium nitrite was effective in experimental models of MI. Its effects were evident when it was applied before the occlusion, but also when it was applied as a peri-conditioning agent [182–184]. Studies on the Langendorff isolated and perfused heart model showed that nitrite infusion before ischemia reduced the infarct lesion and induced a better recovery of left ventricular function [185]. A study using ischemia/reperfusion models in mice was performed to investigate nitrite’s cardioprotective role. In this study, left coronary artery occlusion caused ischemia for 30 minutes, and subsequent reperfusion lasted for 24 h. Sodium nitrite was applied during myocardial ischemia, and exhibited protective effects on cardiomyocyte necrosis [186]. Data from the literature show that low-molecular-weight thiol compounds react with NO to form S-nitrosothiols (RSNOs), which have similar activity to NO.

Normal vascular endothelial cells can alter the side effects of Hcy by increasing NO production and promoting the production of S-nitrosohomocysteine (SNOHcy). In this way, endothelial cells protect the blood vessel wall from the harmful effects of Hcy. Prolonged exposure of endothelial cells to Hcy can disrupt NO response. Disruption can happen due to reduced NO production by eNOS or to reduced bioavailability of NO (through the formation of SNOHcy from Hcy and NO). Experimental studies in rats showed that elevated levels of Hcy can significantly mitigate the systemic NO-mediated vasorelaxation induced by nitric oxide donors. SNOHcy, S-nitrocysteine (SNOcys) and sodium nitroprusside (SNP) function as NO donors. They all have similar hypotensive effects, which can be similarly impaired in HHcy. SNOHcy releases NO (SNOHcy \rightarrow Hcy + NO) to achieve a vasodilatory effect. If Hcy is in excess (Hcy infusion), the reaction moves in the direction of SNOHcy production (Hcy + NO \rightarrow SNOHcy) and not in the direction of NO release. This is the reason the bioavailability of NO is lower, leading to less efficient vasodilatation [187].

Hcy reduces the activity of intracellular glutathione peroxidase [188]. Decreased glutathione peroxidase activity can make NO more susceptible to oxidative inactivation, which in turn reduces NO bioavailability. These two pathways can be complementary [187]. As mentioned earlier, Hcy acts as a procoagulant. HHcy is responsible for accelerated platelet activation, accelerated coagulation, and decreased fibrinolysis, all of which lead to posttranslational changes in fibrin fibers [189]. In preclinical experiments, folic acid treatment increased plasma folate concentrations and suppressed thrombosis in mice deficient in apolipoprotein E and LDL receptors [190]. A double-blind study including 158 healthy siblings of patients with homocysteinemia with premature atherothrombotic disease demonstrated a connection between folic acid and vitamin B6 administration and reduced incidence of pathological changes in electrocardiographic stress tests [191]. The exact mechanism for the development of accelerated thrombosis has not been elucidated, but it is suggested that reduced NO bioavailability, which stimulates platelet activation, is the main reason [192].

5.2. Hydrogen Sulfide

H₂S results from endogenous sources (cysteine) found in blood and other tissues. H₂S is a product of cysteine in the process of desulfurization. The production of H₂S is catalyzed by the same enzymes, i.e., CBS and CSE, and 3-mercaptopyruvate sulfurtransferase (3-MST), involved in transsulfuration. H₂S can be synthesized from cystathionine by CSE. H₂S can also be produced by CBS from cysteine. This cysteine is created from cystathionine (formed in the reaction of serine and Hcy). After the cysteine aminotransferase (CAT) forms 3-mercaptopyruvate (3MP), the 3MP can be broken down with 3-MST to form H₂S. There is a lot of CSE in the heart and little CBS; thus, the heart is considered to be a significant source of H₂S production [12]. Changes in H₂S metabolism can lead to hypertension, diabetes, cirrhosis, neurodegenerative diseases, asthma, erectile dysfunction, atherosclerosis, HF, inflammation, and sepsis [193,194]. H₂S in the cardiovascular system has a cardioprotective role; it affects vasodilation and the reduction of blood pressure. There is a strong bond between H₂S and NO. This is based on ability of H₂S to activate eNOS and increase the amount of NO [14]. NO can increase H₂S biosynthesis by CSE activation [195]. Figure 2 shows the crosslink of these gasotransmitters, and their effects on the cardiovascular system. H₂S also plays a significant role in myocardial fibrosis, which can cause the development of HF. It also inhibits the TGF- β 1/Smad3 signaling pathway, reducing collagen deposition in the myocardium [196].

H₂S, like many other molecules, can have beneficial effects by acting through various pathways, but the main one is associated with oxidative stress and NO [197]. Ischemia/reperfusion injury of the myocardium leads to tissue destruction and HF. Although reperfusion improves ischemia, it also leads to changes such as inflammation and oxidative stress [198]. An in vivo ischemia/reperfusion model in mice showed that H₂S acts in favor of cardio protection by means of inhibiting inflammation, reducing the size of the infarcted zone, and preserving the structure and function of the left ventricle. This

experiment showed that the modulation of the endogenous production of H₂S by overexpressing cardiac CSL leads to a significant reduction of myocardial injury. This suggests that the administration of H₂S or its increased endogenous production may be significant for clinical use in ischemic disorders [199]. The mechanisms of H₂S cardioprotection in ischemia/reperfusion injury include the maintenance of mitochondrial function, the reduction of apoptosis in heart muscle cells, anti-inflammatory response, and antioxidant effects. Mitochondria play a role in energy production and cell survival. After MI, they maintain oxidative phosphorylation, and thus protect the cells. In vitro experiments showed reduced oxygen consumption after treatment with H₂S [199]. During reperfusion, H₂S maintains mitochondrial function by increasing the efficiency of complexes I and II in the electron transport chain.




Figure 2. Relationship between H₂S, NO and CO, and their roles in cardioprotection. CAT—cysteine aminotransferase, CBS—cystathionine β-synthase, CSE—cystathionine γ-lyase, CO—carbon monoxide, eNOS—endothelial nitric oxide synthase, HO-1—heme oxygenase-1, H₂S—hydrogen sulfide, NO—nitric oxide, 3-MP—3-mercaptopyrivate, 3-MST—3-mercaptopyrivate sulfurtransferase. Substrates are represented in the oval boxes and enzymes in the bubbles next to the line pointing to the product. Arrow pointing up (↑) represents increased process or function, and arrow pointing down (↓) represents decreased process or function.

In ischemia, ROS can impair mitochondrial function, which may exacerbate myocardial damage [200]. High doses of this gasotransmitter can inhibit cytochrome C oxidase, and thus reduce cellular respiration, leading the cell to a state of reduced metabolism, thereby protecting the cell [201]. This inhibition of respiration limits ROS production, protecting the myocardium from ischemia/reperfusion injury [200]. H₂S has an antioxidant effect via the Nrf-2 signaling pathway. Nrf-2 can be translocated from cytosol to the nucleus, and it can induce various antioxidant proteins there. It stimulates antioxidant protection and reduces oxidative stress. Studies have shown that diallyl trisulfide (DATS), a donor of H₂S, after MI, allows the translocation of Nrf-2 from the cytosol into the nucleus, maintaining unchanged its total amount in the cell [202]. Activated Nrf-2 can activate detoxification

genes in the nucleus. This leads to activation of heme oxygenase 1 (HO-1), superoxide dismutase, and catalase. H₂S also increases glutathione levels and reduces oxidative stress. Apart from the fact that H₂S itself has an antioxidant effect, it can also act together with NO, because it activates eNOS and increases the bioavailability of NO. H₂S can prevent inflammation, because it prevents the adhesion of leukocytes to the wall of the blood vessels and inhibits the adhesion and expression of adhesion molecules. It also slows down the remodeling of the heart and promotes angiogenesis in congestive HF. Angiogenesis involves the remodeling of the extracellular matrix and its incorporation into capillaries [200]. HHcy affects the synthesis of H₂S. Under physiological conditions, the concentration of total cysteine in plasma is higher than the concentration of Hcy. Cysteine is the source of 70% of H₂S. High Hcy concentration overpowers cysteine, and Hcy becomes a key source of H₂S. It has been shown that Hcy can reduce H₂S production [203]. Lower H₂S levels were found in mice with HHcy [204] and in mice with intracerebrally administered Hcy [205].

5.3. Carbon Monoxide

Endogenous CO is formed by the degradation of heme in the reaction catalyzed by heme oxygenases subtypes 1 and 2 (HO-1, HO-2). This reaction produces iron ion (Fe²⁺), biliverdin and CO. Biliverdin rapidly converts to bilirubin in presence of oxygen and NADPH. This reaction is significant for bile and iron metabolism. In cardiomyocytes, the expression of HO-1 and the HO-2 is significant. HO-1 expression is inducible, while HO-2 is constitutive. Various stressful conditions, including MI, can lead to increased HO-1 expression. Induction of HO-1 is particularly strong in ischemia/reperfusion models. In these models, HO-1 is increased in coronary arteries, which contributes to the maintenance of perfusion via vasodilatation [206]. In addition to this effect, CO shows anti-apoptotic, antihypertensive and anti-inflammatory effects (Figure 2) [164,206–208]. At low concentrations, CO inhibits the expression of proinflammatory cytokines TNF- α , IL-1 β , macrophage inflammatory protein-1 β (MIP-1 β), and increases the expression of anti-inflammatory cytokines, such as IL-10 [209].

Various CO-releasing molecules (CORMs) reduce the size of the infarcted lesion without affecting arterial blood pressure, heart rate, and carboxyhemoglobin concentration [71]. In a model of MI induced by ligation of the left descending artery in mice, CO-releasing molecules improve left ventricular remodeling [210]. Pretreatment with CORM 24 to 72 h before occlusion in mice reduced the size of the infarcted zone [211]. Synthetic CO-releasing molecules have beneficial effects on the structural and functional recovery of the myocardium in models of left descending coronary artery ligation in rats. They also increase the number of cardiomyocytes in damaged areas, as well as blood vessels [212]. CO and NO have similar effects (Figure 2), both acting as signaling molecules and messengers. CO, as a signaling molecule, has prolonged effects on the cardiovascular system compared to NO and H₂S [213]. H₂S can induce activity of HO-1 and increase CO production [214]. The effects of CO on the cardiovascular system include: modulation of autonomic nervous system activity on pacemaker cells and other muscle cells of the heart, vasodilation, changes in heart rate and contraction strength [213]. CO alters the electrophysiological activity of the heart either by its direct action or by its effects on the signaling pathways in the cell. The level of CO also changes the amount of NO by nitrosylation of ion channels and ion transporters, or directly by specific signaling molecules. NO/S nitrosylation increases K⁺ current, which creates a resting potential in the heart muscle. It can also affect the turnover of Na⁺/K⁺ ATPase in the hypoxic heart, and cause the release of Ca²⁺ from the sarcoplasmic reticulum via the ryanodine receptor complex [213]. Electrophysiological and contractile changes affected by CO are caused by an increase in the late Na⁺ current in the heart. NO is a messenger in this process [215,216]. CO acts on soluble guanylyl cyclase, by binding it and increasing the amount of cGMP. This means of forming cGMP is controversial, because the activation of soluble guanylyl cyclase caused by CO induction is lower than that caused by NO induction. In cases where NO is present, the interaction of guanylyl cyclase with CO results in a small amount of cGMP. Some endogenous substances

can increase the sensitivity of soluble guanylyl cyclase to CO [217]. The literature shows that CO inhibits CBS, an enzyme involved in H₂S production. CO-dependent inhibition of CBS can influence the remethylation cycle, and is associated metabolic pathways for methionine maintenance and polyamine production [218].

6. Conclusions

Vitamin B6 and folic acid deficiency can cause Hhcy, which is associated with myocardial injury. Models of MI and HF include complex processes: oxidative stress, endothelial dysfunction, gasotransmitter activity, inflammation, and extracellular fibrous changes. The supplementation of vitamin B6 and folic acid in experimental models of MI and HF could improve heart function. Treatment with vitamin B6 and folic acid could improve vasodilatation, coronary flow, reduce oxidative stress and inflammation.

Author Contributions: Conceptualization, D.M.D., R.S. and M.P.S.; writing—original draft preparation, Z.B. and T.S.; writing—review and editing, D.M.D., M.P.S. and R.S.; visualization, Z.B.; supervision, D.M.D., M.P.S., R.S., N.P. and A.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

3MP	3-mercaptopyruvate
3-MST	3-mercaptopyruvate sulphurtransferase
5-MTHF	5-methyltetrahydrofolate
5'NT	Nucleotidase
ADA	Adenosine deaminase
ADMA	Asymmetric dimethylarginine
AdoMet	S-adenosyl methionine
ALP	Alkaline phosphatase
AMI	Acute myocardial infarction
AST	Aspartate aminotransferase
BH4	Tetrahydrobiopterin
BHMT	Betaine homocysteine methyltransferase
BNP	B-type natriuretic peptide
CAD	Coronary artery disease
Cbl	Cobalamin
Cat	Cationic amino acids
CAT	Cysteine aminotransferase
CBS	Cystathionine β-synthase
CK	Creatine kinase
CO	Carbon monoxide
CORM	CO-releasing molecules
CRP	C-reactive protein
CSE	Cystathionine γ-lyase
DALYs	Disability-adjusted life years
DATS	Diallyl trisulfide
DDAH	Dimethylarginine dimethylaminohydrolase
DHF	Dihydrofolate
DHFR	Dihydrofolate reductase
DMG	Dimethylglycine
dTMP	Deoxythymidine monophosphate
dUMP	Deoxyuridine monophosphate

DVT	Deep venous thrombosis
eNOS	Endothelial NOS
Gal-3	Galectin-3
GC	Guanylate cyclase
GDF-15	Growth differentiation factor-15
GGT	Gamma-glutamyl transferase
GPx	Glutathione peroxidase
GR	Glutathione reductase
GSH	Reduced glutathione
GSSG	Oxidized glutathione
GST	Glutathion S-transferase
H ₂ S	Hydrogen sulphide
Hcy	Homocysteine
HDL	High density lipoprotein
HF	Heart failure
H-FABP	Heart fatty acid-binding protein
HHcy	Hyperhomocysteinemia
HO	Haem oxygenase
hs-cTN	High sensitive cardiac troponin
hs-Tn	High sensitive troponin
HTL	Homocystein thiolactone
IL-1	Inerleukin-1
IL-1 β	Interleukin-1 β
IL-18	Interleukin-18
IL-6	Interleukin-6
iNOS	Inducibile NOS
IP ₃	Inositol triphosphate
ISO	Isoprenaline
LAD	Left anterior descending
LCA	Left coronary artery
LDH	Lactate dehydrogenase
LDL	Low density lipoprotein
LDLR	Low density lipoprotein receptor
Lp-PLA A2	Phospholipase A2 associated lipoprotein
LVEDV	Left venticle end-diastolic volume
LVEF	Left ventricular ejection fraction
MAPK	Mitogen-activated protein kinases
MAT	Methionine adenosyltransferase
MDA	Malondialdehyde
MetRS	Methionyl-tRNA synthetase
MI	Myocardial infarction
MIP-1 β	Macrophage inflammatory protein-1 β
MMP-2	Matrix metalloproteinase-2
MMP-9	Matrix metalloproteinase-9
MMPs	Matrix metalloproteinases
MS	Methionine syntase
MSR	Methionine syntase reductase)
MYO	Myoglobin
NAD ⁺	Nicotinamide adenine dinucleotide
NF- κ B	Nuclear factor kappa B
NMDA	N-methyl-D-aspartate
Nmnat	Nicotinamide mononucleotide adenyl transferase
nNOS	Neuronal NOS
NO	Nitric oxide
NOS	Nitric oxide synthase
NS	Nucleosidase
NT-proBNP	N-terminal prohormone B-type natriuretic peptide
PKA	Protein kinase type A

PKC	Protein kinase type C
PLP	Pyridoxal phosphate
PON 1	Paraoxonase 1
PTX-3	Petraxin
RAAS	Renin-angiotensin-aldosterone system
ROS	Reactive oxygen species
RSNOs	S-nitrosothiols
SAHH	S-adenosyl homocysteine hydrolase
SAM	S-adenosyl methionine
sCD40L	Soluble ligand CD40
SERCA2a	Sarcoplasmic reticulum atpase 2a
SHMT	Serine hydroxymethyltransferase
SNOCys	S-nitrocysteine
SNOHyc	S-nitrosohomocysteine
SNP	Sodium nitroprusside
SNS	Sympathetic nervous system
SOD	Superoxide dismutase
THF	Tetrahydrofolate
TNFR 1	TNF- α receptor-1
TNFR 2	TNF- α receptor-2
TNF- α	Tumor necrosis factor- α
TYMS	Thymidylate syntase
VCAM-1	Vascular cell adhesion molecule/protein 1
VLDL	Very low-density lipoprotein
vWF	Von Willebrand factor
ECG	Electrocardiography
XO	Xanthine oxidase

References

- Roth, G.A.; Mensah, G.A.; Johnson, C.O.; Addolorato, G.; Ammirati, E.; Baddour, L.M.; Barengo, N.C.; Beaton, A.; Benjamin, E.J.; Benziger, C.P.; et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update From the GBD 2019 Study. *J. Am. Coll. Cardiol.* **2020**, *76*, 2982–3021. [[CrossRef](#)] [[PubMed](#)]
- Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. *Lancet* **2012**, *380*, 2095–2128. [[CrossRef](#)]
- Paganelli, F.; Mottola, G.; Fromonot, J.; Marlinge, M.; Deharo, P.; Guieu, R.; Ruf, J. Hyperhomocysteinemia and cardiovascular disease: Is the adenosinergic system the missing link? *Int. J. Mol. Sci.* **2021**, *22*, 1690. [[CrossRef](#)] [[PubMed](#)]
- Mundi, S.; Massaro, M.; Scoditti, E.; Carluccio, M.A.; Van Hinsbergh, V.W.M.; Iruela-Arispe, M.L.; De Caterina, R. Endothelial permeability, LDL deposition, and cardiovascular risk factors—A review. *Cardiovasc. Res.* **2018**, *114*, 35–52. [[CrossRef](#)]
- Van Guldener, C.; Nanayakkara, P.W.B.; Stehouwer, C.D.A. Homocysteine and blood pressure. *Curr. Hypertens. Rep.* **2003**, *5*, 26–31. [[CrossRef](#)]
- Sreckovic, B.; Sreckovic, V.D.; Soldatovic, I.; Colak, E.; Sumarac-Dumanovic, M.; Janeski, H.; Janeski, N.; Gacic, J.; Mrdovic, I. Homocysteine is a marker for metabolic syndrome and atherosclerosis. *Diabetes Metab. Syndr. Clin. Res. Rev.* **2017**, *11*, 179–182. [[CrossRef](#)]
- Kim, J.; Kim, H.; Roh, H.; Kwon, Y. Causes of hyperhomocysteinemia and its pathological significance. *Arch. Pharm. Res.* **2018**, *41*, 372–383. [[CrossRef](#)]
- Djurovic, Z.; Jovanovic, V.; Obrenovic, R.; Djurovic, B.; Soldatovic, I.; Vranic, A.; Jakovljevic, V.; Djuric, D.; Zivkovic, V. The importance of the blood levels of homocysteine, folate and vitamin B12 in patients with primary malignant brain tumors. *J. BUON* **2021**, *25*, 2600–2607.
- Aleksic, D.; Djokic, D.; Golubicic, I.; Jakovljevic, V.; Djuric, D. The importance of the blood levels of homocysteine, folio acid and vitamin B12 in children with malignant diseases. *J. BUON* **2013**, *18*, 1019–1025.
- Blom, H.J.; Smulders, Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. *J. Inherit. Metab. Dis.* **2011**, *34*, 75–81. [[CrossRef](#)]
- Li, Y.N.; Gulati, S.; Baker, P.J.; Brody, L.C.; Banerjee, R.; Kruger, W.D. Cloning, mapping and RNA analysis of the human methionine synthase gene. *Hum. Mol. Genet.* **1996**, *5*, 1851–1858. [[CrossRef](#)] [[PubMed](#)]
- Andreadou, I.; Iliodromitis, E.K.; Rassaf, T.; Schulz, R.; Papapetropoulos, A.; Ferdinandy, P. The role of gasotransmitters NO, H₂S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. *Br. J. Pharmacol.* **2015**, *172*, 1587–1606. [[CrossRef](#)] [[PubMed](#)]

13. Djuric, D.; Jakovljevic, V.; Zivkovic, V.; Srejovic, I. Homocysteine and homocysteine-related compounds: An overview of the roles in the pathology of the cardiovascular and nervous systems. *Can. J. Physiol. Pharmacol.* **2018**, *96*, 991–1003. [[CrossRef](#)] [[PubMed](#)]
14. Kolluru, G.K.; Shen, X.; Kevil, C.G. A tale of two gases: NO and H₂S, foes or friends for life? *Redox Biol.* **2013**, *1*, 313–318. [[CrossRef](#)]
15. Azzini, E.; Ruggeri, S.; Polito, A. Homocysteine: Its possible emerging role in at-risk population groups. *Int. J. Mol. Sci.* **2020**, *21*, 1421. [[CrossRef](#)]
16. Vitvitsky, V.; Mosharov, E.; Tritt, M.; Ataulakhanov, F.; Banerjee, R. Redox regulation of homocysteine-dependent glutathione synthesis. *Redox Rep.* **2003**, *8*, 57–63. [[CrossRef](#)]
17. Chubarov, A.S. Homocysteine thiolactone: Biology and chemistry. *Encyclopedia* **2021**, *1*, 445–459. [[CrossRef](#)]
18. Jakubowski, H. Homocysteine modification in protein structure / function and human disease. *Physiol. Rev.* **2019**, *99*, 555–604. [[CrossRef](#)]
19. Perla-Kaján, J.; Włoczkowska, O.; Ziola-Frankowska, A.; Frankowski, M.; Smith, A.D.; De Jager, C.A.; Refsum, H.; Jakubowski, H. Paraoxonase 1, B vitamins supplementation, and mild cognitive impairment. *J. Alzheimer's Dis.* **2021**, *81*, 1211–1229. [[CrossRef](#)]
20. Borowczyk, K.; Shih, D.M.; Jakubowski, H. Metabolism and neurotoxicity of homocysteine thiolactone in mice: Evidence for a protective role of paraoxonase 1. *J. Alzheimer's Dis.* **2012**, *30*, 225–231. [[CrossRef](#)]
21. Shih, D.M.; Gu, L.; Xia, Y.R.; Navab, M.; Li, W.F.; Hama, S.; Castellani, L.W.; Furlong, C.E.; Costa, L.G.; Fogelman, A.M.; et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. *Nature* **1998**, *394*, 284–287. [[CrossRef](#)] [[PubMed](#)]
22. Bhattacharyya, T.; Nicholls, S.J.; Topol, E.J.; Schmitt, D.; Shao, M.; Brennan, D.M.; Ellis, S.G. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress. *JAMA* **2008**, *299*, 1265–1276. [[CrossRef](#)] [[PubMed](#)]
23. Stanhewicz, A.E.; Kenney, W.L. Role of folic acid in nitric oxide bioavailability and vascular endothelial function. *Nutr. Rev.* **2017**, *75*, 61–70. [[CrossRef](#)] [[PubMed](#)]
24. Stanhewicz, A.E.; Alexander, L.M.; Kenney, W.L. Folic acid supplementation improves microvascular function in older adults through nitric oxide-dependent mechanisms. *Clin. Sci.* **2015**, *129*, 159–167. [[CrossRef](#)] [[PubMed](#)]
25. Pietrzik, K.; Bailey, L.; Shane, B. Folic acid and l-5-methyltetrahydrofolate: Comparison of clinical pharmacokinetics and pharmacodynamics. *Clin. Pharmacokinet.* **2010**, *49*, 535–548. [[CrossRef](#)]
26. Jayedi, A.; Zargar, M.S. Intake of vitamin B₆, folate, and vitamin B₁₂ and risk of coronary heart disease: A systematic review and dose-response meta-analysis of prospective cohort studies. *Crit. Rev. Food Sci. Nutr.* **2019**, *59*, 2697–2707. [[CrossRef](#)]
27. Ntaios, G.; Savopoulos, C.; Grekas, D.; Hatzitolios, A. The controversial role of B-vitamins in cardiovascular risk: An update. *Arch. Cardiovasc. Dis.* **2009**, *102*, 847–854. [[CrossRef](#)]
28. Pusceddu, I.; Herrmann, W.; Kleber, M.E.; Scharnagl, H.; Hoffmann, M.M.; Winklhofer-Roob, B.M.; März, W.; Herrmann, M. Sub-clinical inflammation, telomere shortening, homocysteine, vitamin B₆, and mortality: The Ludwigshafen Risk and Cardiovascular Health Study. *Eur. J. Nutr.* **2020**, *59*, 1399–1411. [[CrossRef](#)]
29. Desouza, C.; Keebler, M.; McNamara, D.B.; Fonseca, V. Drugs affecting homocysteine metabolism. *Drugs* **2002**, *62*, 605–616. [[CrossRef](#)]
30. Miller, J.W.; Nadeau, M.R.; Smith, D.; Selhub, J. Vitamin B-6 deficiency vs folate deficiency: Comparison of responses to methionine loading in rats. *Am. J. Clin. Nutr.* **1994**, *59*, 1033–1039. [[CrossRef](#)]
31. Miller, A. The Methionine-Homocysteine Cycle and Its Effects on Cognitive Diseases. *Altern. Med. Rev.* **2003**, *8*, 7–19. [[PubMed](#)]
32. Yakub, M.; Iqbal, M.P.; Kakepoto, G.N.; Rafique, G.; Memon, Y.; Azam, I.; Mehboobali, N.; Parveen, S.; Haider, G. High prevalence of mild hyperhomocysteinemia and folate, B₁₂ and B₆ deficiencies in an urban population in Karachi, Pakistan. *Pak. J. Med. Sci.* **2010**, *26*, 923–929.
33. Chwatko, G.; Boers, G.H.J.; Strauss, K.A.; Shih, D.M.; Jakubowski, H. Mutations in methylenetetrahydrofolate reductase or cystathionine β-synthase gene, or a high-methionine diet, increase homocysteine thiolactone levels in humans and mice. *FASEB J.* **2007**, *21*, 1707–1713. [[CrossRef](#)]
34. Van Guldener, C.; Robinson, K. Homocysteine and renal disease. *Semin. Thromb. Hemost.* **2000**, *26*, 313–324. [[CrossRef](#)]
35. Van Guldener, C. Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? *Nephrol. Dial. Transplant.* **2006**, *21*, 1161–1166. [[CrossRef](#)] [[PubMed](#)]
36. Morris, M.S.; Bostom, A.G.; Jacques, P.F.; Selhub, J.; Rosenberg, I.H. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. *Atherosclerosis* **2001**, *155*, 195–200. [[CrossRef](#)]
37. Bamashmoos, S.A.; Al-nuzaily, M.A.K.; Al-meeri, A.M.; Ali, F.H.H. Relationship between total homocysteine, total cholesterol and creatinine levels in overt hypothyroid patients. *Springerplus* **2013**, *2*, 423. [[CrossRef](#)]
38. Cicone, F.; Santaguida, M.; My, G.; Mancuso, G.; Papa, A.; Persechino, R.; Virili, C.; Brusca, N.; Tofani, A.; Scopinaro, F.; et al. Hyperhomocysteinemia in acute iatrogenic hypothyroidism: The relevance of thyroid autoimmunity. *J. Endocrinol. Investig.* **2017**, *41*, 831–837. [[CrossRef](#)]
39. Almadori, G.; Bussu, F.; Galli, J.; Cadoni, G.; Zappacosta, B.; Persichilli, S.; Minucci, A.; Giardina, B. Serum folate and homocysteine levels in head and neck squamous cell carcinoma. *Cancer* **2002**, *94*, 1006–1011. [[CrossRef](#)]

40. Kato, I.; Dnistrian, A.M.; Schwartz, M.; Toniolo, P.; Koenig, K.; Shore, R.E.; Akhmedkhanov, A.; Zeleniuch-Jacquotte, A.; Riboli, E. Serum folate, homocysteine and colorectal cancer risk in women: A nested case-control study. *Br. J. Cancer* **1999**, *79*, 1917–1922. [[CrossRef](#)]
41. Sun, C.F.; Haven, T.R.; Wu, T.L.; Tsao, K.C.; Wu, J.T. Serum total homocysteine increases with the rapid proliferation rate of tumor cells and decline upon cell death: A potential new tumor marker. *Clin. Chim. Acta* **2002**, *321*, 55–62. [[CrossRef](#)]
42. Govoruskina, N.; Jakovljevic, V.; Zivkovic, V.; Milosavljevic, I.; Jeremic, J.; Bradic, J.; Bolevich, S.; Omarov, I.A.; Djuric, D.; Radonjic, K.; et al. The role of cardiac N-methyl-D-aspartate receptors in heart conditioning—effects on heart function and oxidative stress. *Biomolecules* **2020**, *10*, 1065. [[CrossRef](#)] [[PubMed](#)]
43. Srejovic, I.; Jakovljevic, V.; Zivkovic, V.; Barudzic, N.; Radovanovic, A.; Stanojlovic, O.; Djuric, D. The effects of the modulation of NMDA receptors by homocysteine thiolactone and dizocilpine on cardiodynamics and oxidative stress in isolated rat heart. *Mol. Cell. Biochem.* **2015**, *401*, 97–105. [[CrossRef](#)] [[PubMed](#)]
44. Milovanovic, P.; Hrnčić, D.; Radotić, K.; Stanković, M.; Mutavdžić, D.; Džonić, D.; Rasić-Marković, A.; Djuric, D.; Stanojlovic, O.; Djuric, M. Moderate hyperhomocysteinemia induced by short-term dietary methionine overload alters bone microarchitecture and collagen features during growth. *Life Sci.* **2017**, *191*, 9–16. [[CrossRef](#)] [[PubMed](#)]
45. Djurić, M.; Mutavdžin, S.; Loncar-Stojiljkovic, D.; Kostić, S.; Čolović, M.; Krstić, D.; Zivković, V.; Jakovljevic, V.; Djurić, D. The effects of certain gasotransmitters inhibition on homocysteine acutely induced changes on rat cardiac acetylcholinesterase activity. *Scr. Med.* **2019**, *50*, 112–116. [[CrossRef](#)]
46. Furchgott, R.; Vanhoutte, P. Endothelium-derived relaxing and contracting factors. *FASEB J.* **1989**, *3*, 2007–2018. [[CrossRef](#)]
47. Jacobsen, D.W. Homocysteine and vitamins in cardiovascular disease. *Clin. Chem.* **1998**, *44*, 1833–1843. [[CrossRef](#)]
48. Karolczak, K.; Olas, B. Mechanism of action of homocysteine and its thiolactone in hemostasis system. *Physiol. Res.* **2009**, *58*, 623–633. [[CrossRef](#)]
49. Lentz, S.R.; Piegors, D.J.; Fernández, J.A.; Erger, R.A.; Arning, E.; Malinow, M.R.; Griffin, J.H.; Bottiglieri, T.; Haynes, W.G.; Heistad, D.D. Effect of hyperhomocysteinemia on protein C activation and activity. *Blood* **2002**, *100*, 2108–2112. [[CrossRef](#)]
50. Raposo, B.; Rodríguez, C.; Martínez-González, J.; Badimon, L. High levels of homocysteine inhibit lysyl oxidase (LOX) and downregulate LOX expression in vascular endothelial cells. *Atherosclerosis* **2004**, *177*, 1–8. [[CrossRef](#)]
51. Zivkovic, V.; Jakovljevic, V.; Djordjevic, D.; Vuletic, M.; Barudzic, N.; Djuric, D. The effects of homocysteine-related compounds on cardiac contractility, coronary flow, and oxidative stress markers in isolated rat heart. *Mol. Cell. Biochem.* **2012**, *370*, 59–67. [[CrossRef](#)] [[PubMed](#)]
52. Zivkovic, V.; Jakovljevic, V.; Pechanova, O.; Srejovic, I.; Joksimovic, J.; Selakovic, D.; Barudzic, N.; Djuric, D.M. Effects of DL-homocysteine thiolactone on cardiac contractility, coronary flow, and oxidative stress markers in the isolated rat heart: The role of different gasotransmitters. *BioMed Res. Int.* **2013**, *2013*, 318471. [[CrossRef](#)] [[PubMed](#)]
53. Uzelac, J.J.; Stanić, M.; Krstić, D.; Čolović, M.; Djurić, D. Effects of homocysteine and its related compounds on oxygen consumption of the rat heart tissue homogenate: The role of different gasotransmitters. *Mol. Cell. Biochem.* **2018**, *444*, 143–148. [[CrossRef](#)]
54. Radenković, M.; Djurić, D.; Janković, R.; Prostran, M. The analysis of transduction mechanisms associated with an acute action of homocysteine on isolated rat femoral artery. *Acta Physiol. Hung.* **2014**, *101*, 448–460. [[CrossRef](#)] [[PubMed](#)]
55. Toroser, D.; Sohal, R.S. Age-associated perturbations in glutathione synthesis in mouse liver. *Biochem. J.* **2007**, *405*, 583–589. [[CrossRef](#)]
56. Prasad, A.; Andrews, N.P.; Padder, F.A.; Husain, M.; Quyyumi, A.A. Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability. *J. Am. Coll. Cardiol.* **1999**, *34*, 507–514. [[CrossRef](#)]
57. Zhang, D.; Chen, Y.; Xie, X.; Liu, J.; Wang, Q.; Kong, W.; Zhu, Y. Homocysteine activates vascular smooth muscle cells by DNA demethylation of platelet-derived growth factor in endothelial cells. *J. Mol. Cell. Cardiol.* **2012**, *53*, 487–496. [[CrossRef](#)]
58. Majors, A.; Ehrhart, A.; Pezacka, E. Hyperhomocysteine as a risk factor for vascular disease Enhanced Collagen Production and Accumulation by Smooth Muscle Cells. *Atheroscler. Thromb. Vasc. Biol.* **1997**, *17*, 2074–2081. [[CrossRef](#)]
59. Todorovic, D.; Stojanovic, M.; Medic, A.; Gopcevic, K.; Mutavdžin, S.; Stanković, S.; Djuric, D. Four weeks of aerobic training affects cardiac tissue matrix metalloproteinase, lactate dehydrogenase and malate dehydrogenase enzymes activities, and hepatorenal biomarkers in experimental hyperhomocysteinemia in rats. *Int. J. Mol. Sci.* **2021**, *22*, 6792. [[CrossRef](#)]
60. Kostić, S.; Mićović, Ž.; Andrejević, L.; Cvetković, S.; Stamenković, A.; Stanković, S.; Obrenović, R.; Labudović-Borović, M.; Hrnčić, D.; Jakovljević, V.; et al. The effects of l-cysteine and N-acetyl-l-cysteine on homocysteine metabolism and haemostatic markers, and on cardiac and aortic histology in subchronically methionine-treated Wistar male rats. *Mol. Cell. Biochem.* **2019**, *451*, 43–54. [[CrossRef](#)]
61. Jeremic, J.; Nikolic Turnic, T.; Zivkovic, V.; Jeremic, N.; Milosavljevic, I.; Srejovic, I.; Obrenovic, R.; Jancic, S.; Rakocevic, M.; Matic, S.; et al. Vitamin B complex mitigates cardiac dysfunction in high-methionine diet-induced hyperhomocysteinemia. *Clin. Exp. Pharmacol. Physiol.* **2018**, *45*, 683–693. [[CrossRef](#)] [[PubMed](#)]
62. Nikolic Turnic, T.; Jakovljevic, V.; Djuric, D.; Jeremic, N.; Jeremic, J.; Milosavljevic, I.; Srejovic, I.; Selakovic, D.; Zivkovic, V. Efficacy of atorvastatin and simvastatin in improving of cardiac function during the different degree of hyperhomocysteinemia. *Can. J. Physiol. Pharmacol.* **2018**, *96*, 1040–1049. [[CrossRef](#)] [[PubMed](#)]

63. Turnic, T.N.; Arsic, A.; Vucic, V.; Petrovic, S.; Ristic-Medic, D.; Zivkovic, V.; Srejovic, I.; Jeremic, J.; Radonjic, T.; Milosavljevic, I.; et al. Hydroxymethylglutaryl coenzyme a reductase inhibitors differentially modulate plasma fatty acids in rats with diet-induced-hyperhomocysteinemia: Is ω -3 fatty acids supplementation necessary? *Front. Physiol.* **2019**, *10*, 892. [[CrossRef](#)]
64. Zhao, J.; Chen, H.; Liu, N.; Chen, J.; Gu, Y.; Chen, J.; Yang, K. Role of hyperhomocysteinemia and hyperuricemia in pathogenesis of atherosclerosis. *J. Stroke Cerebrovasc. Dis.* **2017**, *26*, 2695–2699. [[CrossRef](#)]
65. Wen, J.; Wen, Y.; Zhiliang, L.; Lingling, C.; Longxing, C.; Ming, W.; Qiang, F. A decrease in the percentage of circulating mDC precursors in patients with coronary heart disease: A relation to the severity and extent of coronary artery lesions? *Heart Vessel.* **2013**, *28*, 135–142. [[CrossRef](#)] [[PubMed](#)]
66. Ma, Y.; Peng, D.; Liu, C.; Huang, C.; Luo, J. Serum high concentrations of homocysteine and low levels of folic acid and vitamin B12 are significantly correlated with the categories of coronary artery diseases. *BMC Cardiovasc. Disord.* **2017**, *17*, 37. [[CrossRef](#)]
67. Ebbing, M.; Bleie, Ø.; Ueland, P.; Nordrehaug, J.; Vollset, S.; Refsum, H.; Pederson, E.; Nygard, O. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography. *JAMA* **2008**, *300*, 795–804. [[CrossRef](#)]
68. Wang, Z.M.; Zhou, B.; Nie, Z.L.; Gao, W.; Wang, Y.S.; Zhao, H.; Zhu, J.; Yan, J.J.; Yang, Z.J.; Wang, L.S. Folate and risk of coronary heart disease: A meta-analysis of prospective studies. *Nutr. Metab. Cardiovasc. Dis.* **2012**, *22*, 890–899. [[CrossRef](#)]
69. Cui, R.; Iso, H.; Date, C.; Kikuchi, S.; Tamakoshi, A. Dietary folate and vitamin B6 and B12 intake in relation to mortality from cardiovascular diseases: Japan collaborative cohort study. *Stroke* **2010**, *41*, 1285–1289. [[CrossRef](#)]
70. Cheng, D.; Kong, H.; Pang, W.; Yang, H.; Lu, H.; Huang, C.; Jiang, Y. Supplementation b vitamins improves cognitive function in the middle-aged and elderly with hyperhomocysteinemia. *Nutr. Neurosci.* **2016**, *19*, 461–466. [[CrossRef](#)]
71. Guo, H.; Lee, J.D.; Ueda, T.; Cheng, J.; Shan, J.; Wang, J. Hyperhomocysteinaemia & folic acid supplementation in patients with high risk of coronary artery disease. *Indian J. Med. Res.* **2004**, *119*, 33–37. [[PubMed](#)]
72. Djurić, P.; Mladenović, Z.; Spasić, M.; Jović, Z.; Marić-Kocijančić, J.; Prokić, D.; Subota, V.; Radojičić, Z.; Djurić, D. Hyperhomocysteinemia and inflammatory biomarkers are associated with higher clinical SYNTAX score in patients with stable coronary artery disease. *Vojnosanit. Pregl.* **2021**, *78*, 736–744. [[CrossRef](#)]
73. Iqbal, M.P.; Ishaq, M.; Kazmi, K.A.; Yousuf, F.A.; Mehboobali, N.; Ali, S.A.; Khan, A.H.; Waqar, M.A. Role of vitamins B6, B12 and folic acid on hyperhomocysteinemia in a Pakistani population of patients with acute myocardial infarction. *Nutr. Metab. Cardiovasc. Dis.* **2005**, *15*, 100–108. [[CrossRef](#)] [[PubMed](#)]
74. Li, Y.; Huang, T.; Zheng, Y.; Muka, T.; Troup, J.; Hu, F.B. Folic acid supplementation and the risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. *J. Am. Heart Assoc.* **2016**, *5*, e003768. [[CrossRef](#)]
75. Huo, Y.; Li, J.; Qin, X.; Huang, Y.; Wang, X.; Gottesman, R.F.; Tang, G.; Wang, B.; Chen, D.; He, M.; et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: The CSPPT randomized clinical trial. *JAMA J. Am. Med. Assoc.* **2015**, *313*, 1325–1335. [[CrossRef](#)]
76. Park, J.H.; Saposnik, G.; Ovbiagele, B.; Markovic, D.; Towfighi, A. Effect of B-vitamins on stroke risk among individuals with vascular disease who are not on antiplatelets: A meta-analysis. *Int. J. Stroke* **2016**, *11*, 206–211. [[CrossRef](#)]
77. Toole, J.F.; Malinow, M.R.; Chambless, L.E.; Spence, J.D.; Pettigrew, L.C.; Howard, V.J.; Sides, E.G.; Wang, C.-H.; Stampfer, M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. *JAMA* **2004**, *291*, 565–575. [[CrossRef](#)]
78. The VITATOPS Trial Study B vitamins in patients with recent transient ischaemic attack or stroke in the VITAMINS to prevent stroke (VITATOPS) trial: A randomised, double-blind, parallel, placebo-controlled trial. *Lancet Neurol.* **2010**, *9*, 855–865. [[CrossRef](#)]
79. Saposnik, G.; Ray, J.G.; Sheridan, P.; McQueen, M.; Lonn, E. Homocysteine-lowering therapy and stroke risk, severity, and disability: Additional findings from the HOPE 2 trial. *Stroke* **2009**, *40*, 1365–1372. [[CrossRef](#)]
80. Chrysant, S.G.; Chrysant, G.S. The current status of homocysteine as a risk factor for cardiovascular disease: A mini review. *Expert Rev. Cardiovasc. Ther.* **2018**, *16*, 559–565. [[CrossRef](#)]
81. Hsu, C.-Y.; Chiu, S.-W.; Hong, K.-S.; Saver, J.L.; Wu, Y.-L.; Lee, J.-D.; Lee, M.; Ovbiagele, B. Folic acid in stroke prevention in countries without mandatory folic acid food fortification: A meta-analysis of randomized controlled trials. *J. Stroke* **2018**, *20*, 99–109. [[CrossRef](#)]
82. Zhou, K.; Zhao, R.; Geng, Z.; Jiang, L.; Cao, Y.; Xu, D.; Liu, Y.; Huang, L.; Zhou, J. Association between B-group vitamins and venous thrombosis: Systematic review and meta-analysis of epidemiological studies. *J. Thromb. Thrombolysis* **2012**, *34*, 459–467. [[CrossRef](#)] [[PubMed](#)]
83. Kasthuri, R.S.; Key, N.S. Medical management of venous thromboembolism: What the interventional radiologist needs to know. *Semin. Interv. Radiol.* **2012**, *29*, 3–9. [[CrossRef](#)] [[PubMed](#)]
84. Ekim, M.; Ekim, H.; Yilmaz, Y.K.; Kulah, B.; Polat, M.F.; Gocmen, A.Y. Study on relationships among deep vein thrombosis, homocysteine & related B group vitamins. *Pak. J. Med. Sci.* **2015**, *31*, 398–402. [[CrossRef](#)] [[PubMed](#)]
85. Petersen, J.F.; Larsen, B.S.; Sabbah, M.; Nielsen, O.W.; Kumarathurai, P.; Sajadieh, A. Long-term prognostic significance of homocysteine in middle-aged and elderly. *Biomarkers* **2016**, *21*, 490–496. [[CrossRef](#)]
86. Vizzard, E.; Bonadei, I.; Zanini, G.; Frattini, S.; Fiorina, C.; Raddino, R.; Dei Cas, L. Homocysteine and heart failure: An overview. *Recent Pat. Cardiovasc. Drug Discov.* **2009**, *4*, 15–21. [[CrossRef](#)]

87. Chen, P.; Poddar, R.; Tipa, E.V.; Dibello, P.M.; Moravec, C.D.; Robinson, K.; Green, R.; Kruger, W.D.; Garrow, T.A.; Jacobsen, D.W. Homocysteine metabolism in cardiovascular cells and tissues: Implications for hyperhomocysteinemia and cardiovascular disease. *Adv. Enzym. Regul.* **1999**, *39*, 93–109. [[CrossRef](#)]
88. Fournier, P.; Fourcade, J.; Roncalli, J.; Salvayre, R.; Galinier, M.; Causse, E. Homocysteine in chronic heart failure. *Clin. Lab.* **2015**, *61*, 1137–1145. [[CrossRef](#)]
89. Qujeq, D.; Omran, T.S.; Hosini, L. Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. *Clin. Biochem.* **2001**, *34*, 97–101. [[CrossRef](#)]
90. Iqbal, N.S.; Wu, Y.; Hazen, S.; Tang, W.H.W. Elevated plasma homocysteine identifies patients with chronic heart failure at increased cardiovascular risk. *J. Card. Fail.* **2012**, *18*, S87. [[CrossRef](#)]
91. Zheng, M.; Zou, C.; Li, M.; Huang, G.; Gao, Y.; Liu, H. Folic acid reduces tau phosphorylation by regulating PP2A methylation in streptozotocin-induced diabetic mice. *Int. J. Mol. Sci.* **2017**, *18*, 861. [[CrossRef](#)] [[PubMed](#)]
92. Williams, K.T.; Garrow, T.A.; Schalinske, K.L. Type I diabetes leads to tissue-specific DNA hypomethylation in male rats. *J. Nutr.* **2008**, *138*, 2064–2069. [[CrossRef](#)] [[PubMed](#)]
93. Sudchada, P.; Saokaew, S.; Sridetch, S.; Incampa, S.; Jaiyen, S.; Khaithong, W. Effect of folic acid supplementation on plasma total homocysteine levels and glycemic control in patients with type 2 diabetes: A systematic review and meta-analysis. *Diabetes Res. Clin. Pract.* **2012**, *98*, 151–158. [[CrossRef](#)]
94. Lind, V.; Lauritzen, L.; Kristensen, M.; Ross, A.; Eriksen, J. Effect of folate supplementation on insulin sensitivity and type 2 diabetes: A meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* **2019**, *109*, 1233. [[CrossRef](#)]
95. Mutavdzin, S.; Gopcevic, K.; Stankovic, S.; Jakovljevic Uzelac, J.; Labudovic Borovic, M.; Djuric, D.M. The effect of folic acid administration on cardiac tissue matrix metalloproteinase activity and hepatorenal biomarkers in diabetic rats. *Can. J. Physiol. Pharmacol.* **2019**, *97*, 893–901. [[CrossRef](#)] [[PubMed](#)]
96. Mutavdzin, S.; Gopcevic, K.; Stankovic, S.; Jakovljevic, J.U.; Borovic, M.L.; Djuric, D.D. The effects of folic acid administration on cardiac oxidative stress and cardiovascular biomarkers in diabetic rats. *Oxid. Med. Cell. Longev.* **2019**, *2019*, 1342549. [[CrossRef](#)]
97. Wu, T.G.; Li, W.H.; Lin, Z.Q.; Wang, L.X. Effects of folic acid on cardiac myocyte apoptosis in rats with streptozotocin-induced diabetes mellitus. *Cardiovasc. Drugs Ther.* **2008**, *22*, 299–304. [[CrossRef](#)]
98. Nix, W.A.; Zirwes, R.; Bangert, V.; Kaiser, R.P.; Schilling, M.; Hostalek, U.; Obeid, R. Vitamin B status in patients with type 2 diabetes mellitus with and without incipient nephropathy. *Diabetes Res. Clin. Pract.* **2015**, *107*, 157–165. [[CrossRef](#)]
99. Abdullah, K.M.; Abul Qais, F.; Hasan, H.; Naseem, I. Anti-diabetic study of vitamin B6 on hyperglycaemia induced protein carbonylation, DNA damage and ROS production in alloxan induced diabetic rats. *Toxicol. Res.* **2019**, *8*, 568–579. [[CrossRef](#)]
100. Mascolo, E.; Verni, F. Vitamin B6 and diabetes: Relationship and molecular mechanisms. *Int. J. Mol. Sci.* **2020**, *21*, 3669. [[CrossRef](#)]
101. van der Pol, A.; van Gilst, W.H.; Voors, A.A.; van der Meer, P. Treating oxidative stress in heart failure: Past, present and future. *Eur. J. Heart Fail.* **2019**, *21*, 425–435. [[CrossRef](#)] [[PubMed](#)]
102. Takimoto, E.; Kass, D.A. Role of oxidative stress in cardiac hypertrophy and remodeling. *Hypertension* **2007**, *49*, 241–248. [[CrossRef](#)]
103. Hill, M.F.; Singal, P.K. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. *Am. J. Pathol.* **1996**, *148*, 291–300. [[PubMed](#)]
104. Khaper, N.; Singal, P.K. Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in rats. *J. Am. Coll. Cardiol.* **1997**, *29*, 856–861. [[CrossRef](#)]
105. Khaper, N.; Kaur, K.; Li, T.; Farahmand, F.; Singal, P.K. Antioxidant enzyme gene expression in congestive heart failure following myocardial infarction. *Mol. Cell. Biochem.* **2003**, *251*, 9–15. [[CrossRef](#)] [[PubMed](#)]
106. Van Deel, E.D.; Lu, Z.; Xu, X.; Zhu, G.; Hu, X.; Oury, T.D.; Bache, R.J.; Duncker, D.J.; Chen, Y. Extracellular SOD protects the heart against oxidative stress and hypertrophy after myocardial infarction. *Free Radic. Biol. Med.* **2008**, *44*, 1305–1313. [[CrossRef](#)]
107. Ding, Y.; Li, Y.L.; Zimmerman, M.C.; Davisson, R.L.; Schultz, H.D. Role of CuZn superoxide dismutase on carotid body function in heart failure rabbits. *Cardiovasc. Res.* **2009**, *81*, 678–685. [[CrossRef](#)]
108. Shiomi, T.; Tsutsui, H.; Matsusaka, H.; Murakami, K.; Hayashidani, S.; Ikeuchi, M.; Wen, J.; Kubota, T.; Utsumi, H.; Takeshita, A. Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. *Circulation* **2004**, *109*, 544–549. [[CrossRef](#)]
109. Yoshida, T.; Watanabe, M.; Engelman, D.T.; Engelman, R.M.; Schley, J.A.; Maulik, N.; Ho, Y.; Oberley, T.D.; Das, D.K. Glutathione peroxidase are resistant to myocardial ischemia reperfusion injury. *J. Mol. Cell. Cardiol.* **1996**, *28*, 1759–1767. [[CrossRef](#)]
110. Forgione, M.A.; Cap, A.; Liao, R.; Moldovan, N.I.; Eberhardt, R.T.; Lim, C.C.; Jones, J.; Goldschmidt-Clermont, P.J.; Loscalzo, J. Heterozygous cellular glutathione peroxidase deficiency in the mouse: Abnormalities in vascular and cardiac function and structure. *Circulation* **2002**, *106*, 1154–1158. [[CrossRef](#)]
111. Diguët, N.; Trammell, S.; Tannous, C.; Deloux, R.; Piquereau, J.; Maougenot, N.; Gouge, A.; Grassette, M.; Manoury, B.; Blanc, J.; et al. Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy. *Circulation* **2018**, *137*, 2256–2273. [[CrossRef](#)] [[PubMed](#)]
112. Adamy, C.; Mulder, P.; Khouzami, L.; Andrieu-abadie, N.; Defer, N.; Candiani, G.; Pavoine, C.; Caramelle, P.; Souktani, R.; Le Corvoisier, P.; et al. Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats. *J. Mol. Cell. Cardiol.* **2007**, *43*, 344–353. [[CrossRef](#)] [[PubMed](#)]

113. Bourraindeloup, M.; Adamy, C.; Candiani, G.; Cailleret, M.; Bourin, M.C.; Badoual, T.; Su, J.B.; Adubeiro, S.; Roudot-Thoraval, F.; Dubois-Rande, J.L.; et al. N-Acetylcysteine Treatment normalizes serum tumor necrosis factor- α level and hinders the progression of cardiac injury in hypertensive rats. *Circulation* **2004**, *110*, 2003–2009. [[CrossRef](#)] [[PubMed](#)]
114. Danielyan, K.E.; Simonyan, A.A. Protective abilities of pyridoxine in experimental oxidative stress settings in vivo and in vitro. *Biomed. Pharmacother.* **2017**, *86*, 537–540. [[CrossRef](#)] [[PubMed](#)]
115. Hille, R.; Nishino, T. Xanthine oxidase and xanthine dehydrogenase. *FASEB J.* **1995**, *9*, 995–1003. [[CrossRef](#)]
116. Dhalla, N.S.; Takeda, S.; Elimban, V. Mechanisms of the beneficial effects of vitamin B6 and pyridoxal 5-phosphate on cardiac performance in ischemic heart disease. *Clin. Chem. Lab. Med.* **2013**, *51*, 535–543. [[CrossRef](#)]
117. Endo, N.; Nishiyama, K.; Otsuka, A.; Kanouchi, H.; Taga, M.; Oka, T. Antioxidant activity of vitamin B 6 delays homocysteine-induced atherosclerosis in rats. *Br. J. Nutr.* **2006**, *95*, 1088–1093. [[CrossRef](#)]
118. Deth, R.; Muratore, C.; Benzeery, J.; Pauer-Charnitsky, V.-A.; Waly, M. How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis. *Neurotoxicology* **2010**, *29*, 190–201. [[CrossRef](#)]
119. Mendes, R.; Candido, G.; Mostarda, C.; Sirvente, R.; D'Almeida, V.; Ribeiro, M.; Araujo, A.; Salemi, V.; Rigatto, K.; Irigoyen, M.; et al. Effects of isolated vitamin B6 supplementation on oxidative stress and heart function parameters in experimental hyperhomocysteinemia. *Clin. Biomed. Res.* **2017**, *37*, 73–80. [[CrossRef](#)]
120. Stroes, E.S.G.; Van Faassen, E.E.; Yo, M.; Martasek, P.; Boer, P.; Govers, R.; Rabelink, T.J. Folic acid reverts dysfunction of endothelial nitric oxide synthase. *Circ. Res.* **2000**, *86*, 1129–1134. [[CrossRef](#)]
121. Shirodaria, C.; Antoniades, C.; Lee, J.; Jackson, C.E.; Robson, M.D.; Francis, J.M.; Moat, S.J.; Ratnatunga, C.; Pillai, R.; Refsum, H.; et al. Global improvement of vascular function and redox state with low-dose folic acid: Implications for folate therapy in patients with coronary artery disease. *Circulation* **2007**, *115*, 2262–2270. [[CrossRef](#)] [[PubMed](#)]
122. Li, W.; Tang, R.; Ouyang, S.; Ma, F.; Liu, Z.; Wu, J. Folic acid prevents cardiac dysfunction and reduces myocardial fibrosis in a mouse model of high-fat diet-induced obesity. *Nutr. Metab.* **2017**, *14*, 68. [[CrossRef](#)] [[PubMed](#)]
123. Miller, A.; Mujumdar, V.; Palmer, L.; Bower, J.D.; Tyagi, S.C. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. *Am. J. Hypertens.* **2002**, *15*, 157–163. [[CrossRef](#)]
124. Guo, X.; Cui, H.; Zhang, H.; Guan, X.; Zhang, Z.; Jia, C.; Wu, J.; Yang, H.; Qiu, W.; Zhang, C.; et al. Protective Effect of Folic Acid on Oxidative DNA Damage. *Medicine* **2015**, *94*, e1872. [[CrossRef](#)]
125. Uzelac, J.J.; Djukic, T.; Mutavdzin, S.; Stankovic, S.; Borovic, M.L.; Rakocevic, J.; Milic, N.; Radojevic, A.S.; Vasic, M.; Zigon, N.J.; et al. The influence of subchronic co-application of vitamins B6 and folic acid on cardiac oxidative stress and biochemical markers in monocrotaline-induced heart failure in male wistar albino rats. *Can. J. Physiol. Pharmacol.* **2020**, *98*, 93–102. [[CrossRef](#)]
126. Uzelac, J.J.; Djukic, T.; Radic, T.; Mutavdzin, S.; Stankovic, S.; Rakocevic, J.K.; Borovic, M.L.; Milic, N.; Simic, T.; Savic-Radojevic, A.; et al. Folic acid affects cardiometabolic, oxidative stress, and immunohistochemical parameters in monocrotaline-induced rat heart failure. *Can. J. Physiol. Pharmacol.* **2020**, *98*, 708–716. [[CrossRef](#)]
127. Octavia, Y.; Kararigas, G.; de Boer, M.; Chrifi, I.; Kietadisorn, R.; Swinnen, M.; Duimel, H.; Verheyen, F.K.; Brandt, M.M.; Fliegner, D.; et al. Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase. *J. Cell. Mol. Med.* **2017**, *21*, 3277–3287. [[CrossRef](#)]
128. Djurić, D.; Vušanić, A.; Jakovljević, V. The effects of folic acid and nitric oxide synthase inhibition on coronary flow and oxidative stress markers in isolated rat heart. *Mol. Cell. Biochem.* **2007**, *300*, 177–183. [[CrossRef](#)]
129. Tawakol, A.; Migrino, R.; Aziz, K.; Waitkowska, J.; Holmvang, G.; Alpert, N.; Muller, J.; Fischman, A.; Gewirtz, H. High-dose folic acid acutely improves coronary vasodilator function in patients with coronary artery disease. *J. Am. Coll. Cardiol.* **2005**, *45*, 1580–1584. [[CrossRef](#)]
130. Doshi, S.N.; McDowell, I.F.W.; Moat, S.J.; Payne, N.; Durrant, H.J.; Lewis, M.J.; Goodfellow, J. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. *Circulation* **2002**, *105*, 22–26. [[CrossRef](#)]
131. Scicchitano, P.; Cortese, F.; Gesualdo, M.; De Palo, M.; Massari, F.; Giordano, P.; Ciccone, M.M. The role of endothelial dysfunction and oxidative stress in cerebrovascular diseases. *Free Radic. Res.* **2019**, *53*, 579–595. [[CrossRef](#)] [[PubMed](#)]
132. Minatoguchi, S.; Takemura, G.; Chen, X.H.; Wang, N.; Uno, Y.; Koda, M.; Arai, M.; Misao, Y.; Lu, C.; Suzuki, K.; et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. *Circulation* **2004**, *109*, 2572–2580. [[CrossRef](#)] [[PubMed](#)]
133. Barandon, L.; Couffinhal, T.; Dufourcq, P.; Ezan, J.; Costet, P.; Daret, D.; Deville, C.; Duplâa, C. Frizzled A, a novel angiogenic factor: Promises for cardiac repair. *Eur. J. Cardio-Thorac. Surg.* **2004**, *25*, 76–83. [[CrossRef](#)]
134. Bonvini, R.F.; Hendiri, T.; Camenzind, E. Inflammatory response post-myocardial infarction and reperfusion: A new therapeutic target? *Eur. Heart J. Suppl.* **2005**, *7*, 127–136. [[CrossRef](#)]
135. Ilic, A.; Todorovic, D.; Mutavdzin, S.; Boricic, N.; Nedeljkovic, B.B.; Stankovic, S.; Simic, T.; Stevanovic, P.; Celic, V.; Djuric, D. Translocator protein modulation by 4'-chlorodiazepam and no synthase inhibition affect cardiac oxidative stress, cardiometabolic and inflammatory markers in isoprenaline-induced rat myocardial infarction. *Int. J. Mol. Sci.* **2021**, *22*, 2867. [[CrossRef](#)]
136. Griselli, M.; Herbert, J.; Hutchinson, W.L.; Taylor, K.M.; Sohail, M.; Krausz, T.; Pepys, M.B. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. *J. Exp. Med.* **1999**, *190*, 1733–1739. [[CrossRef](#)]

137. Sekido, N.; Mukaida, N.; Harada, A.; Nakanishi, I.; Watanabe, Y.; Matsushima, K. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. *Nature* **1993**, *365*, 654–657. [[CrossRef](#)]
138. Kereiakes, D.J. Inflammation as a therapeutic target: A unique role for abciximab. *Am. Heart J.* **2003**, *146*, S1–S4. [[CrossRef](#)]
139. Serini, G.; Gabbiani, G. Mechanisms of myofibroblast activity and phenotypic modulation. *Exp. Cell Res.* **1999**, *250*, 273–283. [[CrossRef](#)]
140. Paoletti, R.; Gotto, A.M.; Hajjar, D.P. Inflammation in atherosclerosis and implications for therapy. *Circulation* **2004**, *109*, 20–26. [[CrossRef](#)]
141. Liuzzo, G.; Buffon, A.; Biasucci, L.M.; Gallimore, J.R.; Caligiuri, G.; Vitelli, A.; Altamura, S.; Ciliberto, G.; Rebuzzi, A.G.; Crea, F.; et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. *Circulation* **1998**, *98*, 2370–2376. [[CrossRef](#)] [[PubMed](#)]
142. Cusack, M.R.; Marber, M.S.; Lambiase, P.D.; Bucknall, C.A.; Redwood, S.R. Systemic inflammation in unstable angina is the result of myocardial necrosis. *J. Am. Coll. Cardiol.* **2002**, *39*, 1917–1923. [[CrossRef](#)]
143. Bujak, M.; Dobaczewski, M.; Chatila, K.; Mendoza, L.H.; Li, N.; Reddy, A.; Frangogiannis, N.G. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. *Am. J. Pathol.* **2008**, *173*, 57–67. [[CrossRef](#)] [[PubMed](#)]
144. Abbate, A.; Salloum, F.N.; van Tassell, B.W.; Vecile, E.; Toldo, S.; Seropian, I.; Mezzaroma, E.; Dobrina, A. Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. *PLoS ONE* **2011**, *6*, e27923. [[CrossRef](#)] [[PubMed](#)]
145. Mauro, A.G.; Bonaventura, A.; Mezzaroma, E.; Quader, M.; Toldo, S. NLRP3 Inflammasome in acute myocardial infarction. *J. Cardiovasc. Pharmacol.* **2019**, *74*, 175–187. [[CrossRef](#)]
146. Venkatachalam, K.; Prabhu, S.D.; Reddy, V.S.; Boylston, W.H.; Valente, A.J.; Chandrasekar, B. Neutralization of interleukin-18 ameliorates ischemia/reperfusion-induced myocardial injury. *J. Biol. Chem.* **2009**, *284*, 7853–7865. [[CrossRef](#)]
147. Morris, M.S.; Sakakeeny, L.; Jacques, P.F.; Picciano, M.F.; Selhub, J. Vitamin B-6 intake is inversely related to, and the requirement is affected by, inflammation status. *J. Nutr.* **2010**, *140*, 103–110. [[CrossRef](#)]
148. Vermaak, W.J.H.; Barnard, H.C.; Van Dalen, E.M.S.P.; Potgieter, G.M.; Van Jaarsveld, H.; Myburgh, S.J.S. Compartmentalization of pyridoxal-5'-phosphate during the acute phase of myocardial infarction. *Klin. Wochenschr.* **1988**, *66*, 428–433. [[CrossRef](#)]
149. Vermaak, J.H.; Barnard, H.C.; Potgieter, G.M.; Marx, J. Plasma pyridoxal-5'-phosphate levels in myocardial infarction. *S. Afr. Med. J.* **1986**, *70*, 195–196.
150. Friso, S.; Jacques, P.F.; Wilson, P.W.F.; Rosenberg, I.H.; Selhub, J. Low circulating vitamin B6 is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. *Circulation* **2001**, *103*, 2788–2791. [[CrossRef](#)]
151. Chiang, E.P.I.; Selhub, J.; Bagley, P.J.; Dallal, G.; Roubenoff, R. Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis. *Arthritis Res. Ther.* **2005**, *7*, R1404–R1411. [[CrossRef](#)] [[PubMed](#)]
152. Dusitanond, P.; Eikelboom, J.W.; Hankey, G.J.; Thom, J.; Gilmore, G.; Loh, K.; Yi, Q.; Klijn, C.J.M.; Langton, P.; Van Bockxmeer, F.M.; et al. Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: A randomized substudy of the VITATOPS trial. *Stroke* **2005**, *36*, 144–146. [[CrossRef](#)]
153. Sood, S.; Chelu, M.; Van Oort, R.; Skapura, D.; Santonastasi, M.; Dobrev, D.; Wehrens, X. Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation. *Heart Rhythm* **2008**, *5*, 1047–1054. [[CrossRef](#)] [[PubMed](#)]
154. Li, M.; Chen, J.; Li, Y.S.; Feng, Y.B.; Gu, X.; Shi, C.Z. Folic acid reduces adhesion molecules VCAM-1 expression in aortic of rats with hyperhomocysteinemia. *Int. J. Cardiol.* **2006**, *106*, 285–288. [[CrossRef](#)] [[PubMed](#)]
155. Holt, E.M.; Steffen, L.M.; Moran, A.; Basu, S.; Steinberger, J.; Ross, J.A.; Hong, C.-P.; Sinaiko, A.R. Fruit and vegetable consumption and its relation to markers of inflammation and oxidative stress in adolescents. *J. Am. Diet. Assoc.* **2009**, *109*, 414–421. [[CrossRef](#)]
156. Tousoulis, D.; Kourkouti, P.; Briasoulis, A.; Vogiatzi, G.; Valatsou, A.; Pantopoulou, A.; Oikonomou, E.; Perrea, D.; Stefanadis, C. Divergent effects of folic acid administration on inflammatory status and cholesterol levels in apoE deficient mice. *Int. J. Cardiol.* **2014**, *173*, 608–609. [[CrossRef](#)]
157. Hofmann, M.A.; Lalla, E.; Lu, Y.; Gleason, M.R.; Wolf, B.M.; Tanji, N.; Ferran, L.J.; Kohl, B.; Rao, V.; Kisiel, W.; et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. *J. Clin. Investig.* **2001**, *107*, 675–683. [[CrossRef](#)]
158. Marui, N.; Offermann, M.K.; Swerlick, R.; Kunsch, C.; Rosen, C.A.; Ahmad, M.; Wayne Alexander, R.; Medford, R.M. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. *J. Clin. Investig.* **1993**, *92*, 1866–1874. [[CrossRef](#)]
159. Neish, A.S.; Williams, A.J.; Palmer, H.J.; Whitley, M.Z.; Collins, T. Functional analysis of the human vascular cell adhesion molecule 1 promoter. *J. Exp. Med.* **1992**, *176*, 1583–1593. [[CrossRef](#)]
160. Schreck, R.; Albermann, K.; Baeuerle, P.A. Nuclear factor κ B: An oxidative stress-responsive transcription factor of eukaryotic cells (a review). *Free Radic. Res.* **1992**, *17*, 221–237. [[CrossRef](#)]
161. Kretz-Remy, C.; Mehlen, P.; Mirault, M.E.; Arrigo, A.P. Inhibition of I κ B- α phosphorylation and degradation and subsequent NF- κ B activation by glutathione peroxidase overexpression. *J. Cell Biol.* **1996**, *133*, 1083–1093. [[CrossRef](#)] [[PubMed](#)]
162. Szabo, C. Gaseotransmitters: New frontiers for translational science. *Sci. Transl. Med.* **2010**, *2*, 59ps54. [[CrossRef](#)] [[PubMed](#)]

163. Coletta, C.; Papapetropoulos, A.; Erdelyi, K.; Olah, G.; Módis, K.; Panopoulos, P.; Asimakopoulou, A.; Gerö, D.; Sharina, I.; Martin, E.; et al. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 9161–9166. [[CrossRef](#)]
164. Muchova, L.; Wong, R.J.; Hsu, M.; Morioka, I.; Vitek, L.; Zelenka, J.; Schröder, H.; Stevenson, D.K. Statin treatment increases formation of carbon monoxide and bilirubin in mice: A novel mechanism of in vivo antioxidant protection. *Can. J. Physiol. Pharmacol.* **2007**, *85*, 800–810. [[CrossRef](#)] [[PubMed](#)]
165. Djurić, M.; Kostic, S.; Loncar-Stojiljkovic, D.; Mutavdzin, S.; Colović, M.; Krstic, D.; Stevanovic, P.; Djuric, D. The effects of gasotransmitters inhibition on homocysteine acutely induced changes in oxidative stress markers in rat plasma. *Scr. Med.* **2019**, *50*, 6–12. [[CrossRef](#)]
166. Jones, S.P.; Girod, W.G.; Palazzo, A.J.; Granger, D.N.; Grisham, M.B.; Jourdeuil, D.; Huang, P.L.; Lefer, D.J. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. *Am. J. Physiol. Heart Circ. Physiol.* **1999**, *276*, 1567–1573. [[CrossRef](#)]
167. Calvert, J.W.; Lefer, D.J. Myocardial protection by nitrite. *Cardiovasc. Res.* **2009**, *83*, 195–203. [[CrossRef](#)]
168. Jin, L.; Caldwell, R.B.; Li-Masters, T.; Caldwell, R.W. Homocysteine induces endothelial dysfunction via inhibition of arginine transport. *J. Physiol. Pharmacol.* **2007**, *58*, 191–206.
169. Topal, G.; Brunet, A.; Millanvoye, E.; Boucher, J.L.; Rendu, F.; Devynck, M.A.; David-Dufilho, M. Homocysteine induces oxidative stress by uncoupling of no synthase activity through reduction of tetrahydrobiopterin. *Free Radic. Biol. Med.* **2004**, *36*, 1532–1541. [[CrossRef](#)]
170. Lai, W.K.C.; Kan, M.Y. Homocysteine-induced endothelial dysfunction. *Ann. Nutr. Metab.* **2015**, *67*, 1–12. [[CrossRef](#)]
171. Bir, S.; Kolluru, G.; Fang, K.; Kevil, C. Redox balance dynamically regulates vascular growth and remodeling. *Semin. Cell Dev. Biol.* **2012**, *23*, 745–757. [[CrossRef](#)] [[PubMed](#)]
172. Leiper, J.M.; Vallance, P. The synthesis and metabolism of asymmetric dimethylarginine (ADMA). *Eur. J. Clin. Pharmacol.* **2006**, *62*, 33–38. [[CrossRef](#)]
173. Böger, R.H.; Bode-Böger, S.M.; Tsao, P.S.; Lin, P.S.; Chan, J.R.; Cooke, J.P. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. *J. Am. Coll. Cardiol.* **2000**, *36*, 2287–2295. [[CrossRef](#)]
174. Kumar, A.; Palfrey, H.A.; Pathak, R.; Kadowitz, P.J.; Gettys, T.W.; Murthy, S.N. The metabolism and significance of homocysteine in nutrition and health. *Nutr. Metab.* **2017**, *14*, 78. [[CrossRef](#)]
175. Johnson, G.; Tsao, P.; Leffer, A. Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion. *Crit. Care Med.* **1991**, *19*, 244–252. [[CrossRef](#)]
176. Loke, K.E.; Laycock, S.K.; Mital, S.; Wolin, M.S.; Bernstein, R.; Oz, M.; Addonizio, L.; Kaley, G.; Hintze, T.H. Nitric oxide modulates mitochondrial respiration in failing human heart. *Circulation* **1999**, *100*, 1291–1297. [[CrossRef](#)] [[PubMed](#)]
177. Thomas, D.D. The biological lifetime of nitric oxide: Implications for the perivascular dynamics of NO and O₂. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 355–360. [[CrossRef](#)]
178. Ma, X.I.; Weyrich, A.S.; Lefer, D.J.; Lefer, A.M. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. *Circ. Res.* **1993**, *72*, 403–412. [[CrossRef](#)]
179. Palazzo, A.J.; Jones, S.P.; Girod, W.G.; Anderson, D.C.; Granger, D.N.; Lefer, D.J.; Anthony, J.; Jones, S.P.; Wesley, G.; Anderson, D.C.; et al. Myocardial ischemia-reperfusion injury in CD18- and ICAM-1-deficient mice. *Am. J. Physiol. Heart Circ. Physiol.* **1998**, *275*, H2300–H2307. [[CrossRef](#)]
180. Walter, U.; Gambaryan, S. Roles of cGMP/cGMP-dependent protein kinase in platelet activation. *Blood* **2004**, *104*, 2609. [[CrossRef](#)]
181. Li, J.; Bombeck, C.A.; Yang, S.; Kim, Y.M.; Billiar, T.R. Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes. *J. Biol. Chem.* **1999**, *274*, 17325–17333. [[CrossRef](#)] [[PubMed](#)]
182. Dezfulian, C.; Shiva, S.; Alekseyenko, A.; Pendyal, A.; Beiser, D.G.; Munasinghe, J.P.; Anderson, S.A.; Chesley, C.F.; Vanden Hoek, T.L.; Gladwin, M.T. Nitrite therapy after cardiac arrest reduces reactive oxygen species generation, improves cardiac and neurological function, and enhances survival via reversible inhibition of mitochondrial complex I. *Circulation* **2009**, *120*, 897–905. [[CrossRef](#)] [[PubMed](#)]
183. Hendgen-Cotta, U.B.; Merx, M.W.; Shiva, S.; Schmitz, J.; Becher, S.; Klare, J.P.; Steinhoff, H.J.; Goedecke, A.; Schrader, J.; Gladwin, M.T.; et al. Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 10256–10261. [[CrossRef](#)] [[PubMed](#)]
184. Gonzalez, F.; Shiva, S.; Vincent, P.; Ringwood, L.; Hsu, L.; Hon, Y.; Alteras, A.; Cannon, R.O.; Gladwin, M.; Arai, A. Nitrite anion (NO₂⁻) provides potent cytoprotective and anti-apoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction. *Circulation* **2008**, *117*, 2886–2994. [[CrossRef](#)]
185. Webb, A.; Bond, R.; McLean, P.; Uppal, R.; Benjamin, N.; Ahluwalia, A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 13683–13688. [[CrossRef](#)]
186. Duranski, M.R.; Greer, J.J.M.; Dejam, A.; Jaganmohan, S.; Hogg, N.; Langston, W.; Patel, R.P.; Yet, S.F.; Wang, X.; Kevil, C.G.; et al. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. *J. Clin. Investig.* **2005**, *115*, 1232–1240. [[CrossRef](#)] [[PubMed](#)]
187. Fu, W.Y.; Dudman, N.P.B.; Perry, M.A.; Wang, X.L. Homocysteine attenuates hemodynamic responses to nitric oxide in vivo. *Atherosclerosis* **2002**, *161*, 169–176. [[CrossRef](#)]

188. Upchurch, G.R.; Welche, G.N.; Fabian, A.J.; Freedman, J.E.; Johnson, J.L.; Keaney, J.F.; Loscalzo, J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. *J. Biol. Chem.* **1997**, *272*, 17012–17017. [[CrossRef](#)]
189. Sauls, D.L.; Lockhart, E.; Warren, M.E.; Lenkowski, A.; Wilhelm, S.E.; Hoffman, M. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: A potential mechanism of the thrombotic tendency in hyperhomocysteinemia. *Biochemistry* **2006**, *45*, 2480–2487. [[CrossRef](#)]
190. Tamura, Y.; Inoue, A.; Ijiri, Y.; Naemura, A.; Yamamoto, J. Short- and long-term treatment with folic acid suppresses thrombus formation in atherogenic mice in vivo. *Pathophysiology* **2014**, *21*, 169–175. [[CrossRef](#)]
191. Vermeulen, E.G.J.; Stehouwer, C.D.A.; Twisk, J.W.R.; Van Den Berg, M.; De Jong, S.C.; Mackaay, A.J.C.; Van Campen, C.M.C.; Visser, F.C.; Jakobs, C.A.J.M.; Bulterijis, E.J.; et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: A randomised, placebo-controlled trial. *Lancet* **2000**, *355*, 517–522. [[CrossRef](#)]
192. Welch, G.; Loscalzo, J. Homocysteine and atherothrombosis. *N. Engl. J. Med.* **1998**, *338*, 1042–1050. [[CrossRef](#)] [[PubMed](#)]
193. Lynn, E.G.; Austin, R.C. Hydrogen sulfide in the pathogenesis of atherosclerosis and its therapeutic potential. *Expert Rev. Clin. Pharmacol.* **2011**, *4*, 97–108. [[CrossRef](#)]
194. Wang, R. Physiological implications of hydrogen sulfide: A whiff exploration that blossomed. *Physiol. Rev.* **2012**, *92*, 791–896. [[CrossRef](#)] [[PubMed](#)]
195. Citi, V.; Martelli, A.; Gorica, E.; Brogi, S.; Testai, L.; Calderone, V. Role of hydrogen sulfide in endothelial dysfunction: Pathophysiology and therapeutic approaches. *J. Adv. Res.* **2021**, *27*, 99–113. [[CrossRef](#)]
196. Yang, R.; Jia, Q.; Ma, S.F.; Wang, Y.; Mehmood, S.; Chen, Y. Exogenous H₂S mitigates myocardial fibrosis in diabetic rats through suppression of the canonical Wnt pathway. *Int. J. Mol. Med.* **2019**, *44*, 549–558. [[CrossRef](#)]
197. Gorini, F.; Bustaffa, E.; Chatzianagnostou, K.; Bianchi, F.; Vassalle, C. Hydrogen sulfide and cardiovascular disease: Doubts, clues, and interpretation difficulties from studies in geothermal areas. *Sci. Total Environ.* **2020**, *743*, 140818. [[CrossRef](#)]
198. Polhemus, D.J.; Kondo, K.; Bhushan, S.; Bir, S.C.; Kevil, C.G.; Murohara, T.; Lefer, D.J.; Calvert, J.W. Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis. *Circ. Heart Fail.* **2013**, *6*, 1077–1086. [[CrossRef](#)]
199. Elrod, J.W.; Calvert, J.W.; Morrison, J.; Doeller, J.E.; Kraus, D.W.; Tao, L.; Jiao, X.; Scalia, R.; Kiss, L.; Szabo, C.; et al. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 15560–15565. [[CrossRef](#)]
200. Polhemus, D.J.; Calvert, J.W.; Butler, J.; Lefer, D.J. The cardioprotective actions of hydrogen sulfide in acute myocardial infarction and heart failure. *Scientifica* **2014**, *2014*, 768607. [[CrossRef](#)]
201. Blackstone, E.; Morrison, M.; Roth, M.B. H₂S induces a suspended animation-like state in mice. *Science* **2005**, *308*, 518. [[CrossRef](#)] [[PubMed](#)]
202. Predmore, B.L.; Kondo, K.; Bhushan, S.; Zlatopolsky, M.A.; King, A.L.; Aragon, J.P.; Bennett Grinsfelder, D.; Condit, M.E.; Lefer, D.J. The polysulfide diallyl trisulfide protects the ischemic myocardium by preservation of endogenous hydrogen sulfide and increasing nitric oxide bioavailability. *Am. J. Physiol. Heart Circ. Physiol.* **2012**, *302*, H2410–H2418. [[CrossRef](#)] [[PubMed](#)]
203. Yang, Q.; He, G.W. Imbalance of homocysteine and H₂S: Significance, mechanisms, and therapeutic promise in vascular injury. *Oxid. Med. Cell. Longev.* **2019**, *2019*, 7629673. [[CrossRef](#)]
204. Li, J.J.; Li, Q.; Du, H.P.; Wang, Y.L.; You, S.J.; Wang, F.; Xu, X.S.; Cheng, J.; Cao, Y.J.; Liu, C.F.; et al. Homocysteine triggers inflammatory responses in macrophages through inhibiting CSE-H₂S signaling via DNA hypermethylation of CSE promoter. *Int. J. Mol. Sci.* **2015**, *16*, 12560–12577. [[CrossRef](#)]
205. Li, M.H.; Tang, J.P.; Zhang, P.; Li, X.; Wang, C.Y.; Wei, H.J.; Yang, X.F.; Zou, W.; Tang, X.Q. Disturbance of endogenous hydrogen sulfide generation and endoplasmic reticulum stress in hippocampus are involved in homocysteine-induced defect in learning and memory of rats. *Behav. Brain Res.* **2014**, *262*, 35–41. [[CrossRef](#)] [[PubMed](#)]
206. Peers, C.; Steele, D.S. Carbon monoxide: A vital signalling molecule and potent toxin in the myocardium. *J. Mol. Cell. Cardiol.* **2012**, *52*, 359–365. [[CrossRef](#)]
207. Johnson, R.A.; Teran, F.J.; Durante, W.; Peyton, K.J.; Johnson, F.K. Enhanced heme oxygenase-mediated coronary vasodilation in Dahl salt-sensitive hypertension. *Am. J. Hypertens.* **2004**, *17*, 25–30. [[CrossRef](#)]
208. Stein, A.B.; Bolli, R.; Dawn, B.; Sanganalmath, S.K.; Zhu, Y.; Wang, O.L.; Guo, Y.; Motterlini, R.; Xuan, Y.T. Carbon monoxide induces a late preconditioning-mimetic cardioprotective and antiapoptotic milieu in the myocardium. *J. Mol. Cell. Cardiol.* **2012**, *52*, 228–236. [[CrossRef](#)]
209. Parviz, Y.; Waleed, M.; Vijayan, S.; Adlam, D.; Lavi, S.; Al Nooryani, A.; Iqbal, J.; Stone, G.W. Cellular and molecular approaches to enhance myocardial recovery after myocardial infarction. *Cardiovasc. Revascularization Med.* **2019**, *20*, 351–364. [[CrossRef](#)]
210. Wang, G.; Hamid, T.; Keith, R.J.; Zhou, G.; Partridge, C.R.; Xiang, X.; Kingery, J.R.; Lewis, R.K.; Li, Q.; Rokosh, D.G.; et al. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. *Circulation* **2010**, *121*, 1912–1925. [[CrossRef](#)]
211. Stein, A.B.; Guo, Y.; Tan, W.; Wu, W.J.; Zhu, X.; Li, Q.; Luo, C.; Dawn, B.; Johnson, T.R.; Motterlini, R.; et al. Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction. *J. Mol. Cell. Cardiol.* **2005**, *38*, 127–134. [[CrossRef](#)] [[PubMed](#)]
212. Segersvärd, H.; Lakkisto, P.; Hänninen, M.; Forsten, H.; Siren, J.; Immonen, K.; Kosonen, R.; Sarparanta, M.; Laine, M.; Tikkanen, I. Carbon monoxide releasing molecule improves structural and functional cardiac recovery after myocardial injury. *Eur. J. Pharmacol.* **2018**, *818*, 57–66. [[CrossRef](#)] [[PubMed](#)]
213. Mahan, V. Cardiac function dependence on carbon monoxide. *Med. Gas Res.* **2020**, *10*, 37–46. [[CrossRef](#)] [[PubMed](#)]

214. Głowacka, U.; Brzozowski, T.; Magierowski, M. Synergisms, discrepancies and interactions between hydrogen sulfide and carbon monoxide in the gastrointestinal and digestive system physiology, pathophysiology and pharmacology. *Biomolecules* **2020**, *10*, 445. [[CrossRef](#)] [[PubMed](#)]
215. Abramochkin, D.V.; Haertdinov, N.N.; Porokhnya, M.V.; Zefirov, A.L.; Sitdikova, G.F. Carbon monoxide affects electrical and contractile activity of rat myocardium. *J. Biomed. Sci.* **2011**, *18*, 40. [[CrossRef](#)]
216. Dallas, M.L.; Yang, Z.; Boyle, J.P.; Boycott, H.E.; Scragg, J.L.; Milligan, C.J.; Elies, J.; Duke, A.; Thireau, J.; Reboul, C.; et al. Carbon monoxide induces cardiac arrhythmia via induction of the late Na⁺ current. *Am. J. Respir. Crit. Care Med.* **2012**, *186*, 648–656. [[CrossRef](#)]
217. Farrugia, G.; Szurszewski, J. Carbon monoxide, hydrogen sulfide, and nitric oxide as signaling molecules in the gastrointestinal tract. *Gastroenterology* **2014**, *147*, 303–313. [[CrossRef](#)]
218. Hishiki, T.; Yamamoto, T.; Morikawa, T.; Kubo, A.; Kajimura, M.; Suematsu, M. Carbon monoxide: Impact on remethylation/transsulfuration metabolism and its pathophysiologic implications. *J. Mol. Med.* **2012**, *90*, 245–254. [[CrossRef](#)]